var title_f41_22_42336="Finger stretch exercise";
var content_f41_22_42336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Finger stretch exercise for trigger finger",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Massage the palm and base of the fingers with lanolin cream for five minutes. Stretch the affected fingers back with gentle pressure. Perform sets of 15 to 20 per day.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42336=[""].join("\n");
var outline_f41_22_42336=null;
var title_f41_22_42337="Patient information: Ileus (The Basics)";
var content_f41_22_42337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16945\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/22/10595\">",
"         Patient information: Food poisoning (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/39/6770\">",
"         Patient information: Small bowel obstruction (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/3/9267\">",
"         Patient information: Viral gastroenteritis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/30/29156\">",
"         Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ileus (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ileus-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H281896444\">",
"      <span class=\"h1\">",
"       What is an ileus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An ileus is a condition in which the small intestine doesn&rsquo;t work normally (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"mobipreview.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). Normally, the small intestine&rsquo;s muscles squeeze to move air, fluid, and food through it. But in an ileus, the small intestine has trouble moving the air, fluid, and food along. These things then get stuck in the small intestine and cause symptoms.",
"     </p>",
"     <p>",
"      An ileus can happen in children and adults.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H281896451\">",
"      <span class=\"h1\">",
"       What causes an ileus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different things can cause an ileus, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Surgery, especially belly surgery",
"       </li>",
"       <li>",
"        Infections, such as infections of the intestine or inside of the belly",
"       </li>",
"       <li>",
"        A belly injury",
"       </li>",
"       <li>",
"        Certain medicines, such as strong pain medicines",
"       </li>",
"       <li>",
"        Not enough blood flow to the intestines",
"       </li>",
"       <li>",
"        Conditions that affect the body&rsquo;s muscles and nerves",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H281896458\">",
"      <span class=\"h1\">",
"       What are the symptoms of an ileus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        Belly swelling and bloating",
"       </li>",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        Not being able to have a bowel movement or pass gas",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H281896465\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. Your doctor or nurse will ask about your symptoms and do an exam. To find out what&rsquo;s causing your ileus, he or she will probably do blood tests and imaging tests. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p>",
"      The imaging tests can include an X-ray, CT scan, or a series of X-rays called a &ldquo;GI series.&rdquo; For the CT scan and GI series, you will drink a liquid called &ldquo;contrast&rdquo; beforehand. The contrast will show up on the CT scan or X-rays.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H281896472\">",
"      <span class=\"h1\">",
"       How is an ileus treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your symptoms and what&rsquo;s causing your ileus. All people with an ileus are treated in the hospital.",
"     </p>",
"     <p>",
"      To treat your symptoms and help you feel better, your doctor can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Give you fluids and nutrition through an IV (a small tube that goes into your vein)",
"       </li>",
"       <li>",
"        Put a thin tube called a &ldquo;nasogastric tube&rdquo; in your nose, down your esophagus, and into your stomach &ndash; The tube can suck up the fluid and air in your stomach. This will make your stomach feel better and help keep you from vomiting.",
"       </li>",
"       <li>",
"        Give you medicine to help your intestine start working normally again",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If recent surgery caused your ileus, you might not need any other treatment. That&rsquo;s because an ileus that happens after surgery usually gets better on its own in a few days.",
"     </p>",
"     <p>",
"      If a medicine caused your ileus, your doctor will stop that medicine. He or she will also treat any other condition causing your ileus, if the condition can be treated.",
"     </p>",
"     <p>",
"      People with an ileus do not usually need surgery. But they might if their condition is severe.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H281896531\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/39/6770?source=see_link\">",
"       Patient information: Small bowel obstruction (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/3/9267?source=see_link\">",
"       Patient information: Viral gastroenteritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/22/10595?source=see_link\">",
"       Patient information: Food poisoning (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/30/29156?source=see_link\">",
"       Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/22/42337?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16945 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42337=[""].join("\n");
var outline_f41_22_42337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281896444\">",
"      What is an ileus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281896451\">",
"      What causes an ileus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281896458\">",
"      What are the symptoms of an ileus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281896465\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281896472\">",
"      How is an ileus treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281896531\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16945\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/22/10595?source=related_link\">",
"      Patient information: Food poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/39/6770?source=related_link\">",
"      Patient information: Small bowel obstruction (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/3/9267?source=related_link\">",
"      Patient information: Viral gastroenteritis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_22_42338="Partial anomalous pulmonary venous connection";
var content_f41_22_42338=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1156px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/57752/papvr_conv.mp4?title=Partial+anomalous+pulmonary+venous+connection\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    Partial anomalous pulmonary vein connection to the innominate vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 416px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A catheter injects contrast into the left pulmonary artery. The left upper lobe segment drains to a vertical vein that connects to the distal innominate vein before returning to the right atrium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Brian Soriano.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42338=[""].join("\n");
var outline_f41_22_42338=null;
var title_f41_22_42339="Skin anatomy PI";
var content_f41_22_42339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F70895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F70895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Epidermis of the skin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42339=[""].join("\n");
var outline_f41_22_42339=null;
var title_f41_22_42340="Squamous CA cavitation Gross";
var content_f41_22_42340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cavitary squamous cell carcinoma of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripherally located squamous cell carcinoma with extensive central necrosis and cavitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42340=[""].join("\n");
var outline_f41_22_42340=null;
var title_f41_22_42341="Dress 2";
var content_f41_22_42341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Drug reaction with eosinophilia and systemic symptoms (DRESS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse and confluent rash in a patient with DRESS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42341=[""].join("\n");
var outline_f41_22_42341=null;
var title_f41_22_42342="Microbiology of Lyme disease";
var content_f41_22_42342=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology of Lyme disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/22/42342/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/22/42342/contributors\">",
"     Alan G Barbour, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/22/42342/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/22/42342/contributors\">",
"     Allen C Steere, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/22/42342/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/22/42342/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/22/42342/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1776078715\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease is the most common tick-borne disease in the United States, Canada, and Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is a bacterial infection caused by members of the Borrelia species, B. burgdorferi in North America, and primarily by B. afzelii and B. garinii in Europe and Asia. The reservoirs in nature are several species of small mammals and birds. Humans acquire the infection not from direct contact with these vertebrates, but from the bite of an infected tick of the genus Ixodes. The infection begins in the skin at the site of the tick bite. From there, the spirochetes may disseminate in the blood to other tissues and organs. The usual manifestations of Lyme disease involve the skin, joints, heart, and nervous system.",
"   </p>",
"   <p>",
"    In the early 20th century, erythema migrans and Bannwarth&rsquo;s syndrome, which are now known to be skin and neurologic manifestations of Lyme borreliosis, were described in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/3\">",
"     3",
"    </a>",
"    ]. Lyme disease was first described in North America in 1977 as \"Lyme arthritis\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/4\">",
"     4",
"    </a>",
"    ], and the etiologic agent was identified in 1982 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microbiology of Lyme disease will be reviewed here. Issues related to immunopathogenesis, epidemiology, prevention, clinical manifestations, diagnosis, and therapy of Lyme disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26552?source=see_link\">",
"     \"Immunopathogenesis of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3960?source=see_link\">",
"     \"Prevention of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26263?source=see_link\">",
"     \"Evaluation of a tick bite for possible Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7225?source=see_link\">",
"     \"Lyme disease: Clinical manifestations in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27498?source=see_link\">",
"     \"Treatment of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342592157\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND GENOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The members of Borrelia species are spirochetes, which are motile, spiral, or wavy bacteria that are only distantly related to gram-negative and gram-positive pathogens. The genomes of B. burgdorferi, B. afzelii, and B. garinii comprise small linear chromosomes of approximately 1000 kb, and 17 to 21 linear and circular plasmids totaling another 400 to 500 kb [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/6-8\">",
"     6-8",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    Spirochetes have two cellular membranes like gram-negative bacteria, but their flagella, the organelles of motility, are uniquely located between in the inner and outer membrane rather than on the surface. B. burgdorferi is 8 to 30 microns in length and about 0.2 microns in width. Their narrowness accounts for the inability to see unstained or Gram stained cells by standard light microscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342592788\">",
"    <span class=\"h1\">",
"     BORRELIA PROTEINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some Borrelia antigens are encoded by genes on the chromosome; these include flagellin, the major structural protein of flagella, with an apparent size by electrophoresis of 41 kDa. Other chromosomally-encoded antigens include heat shock proteins (60 and 73 kDa), integral membrane proteins (39 kDa and 66 kDa), and proteins of unknown function (58 kDa and 93 kDa).",
"   </p>",
"   <p>",
"    A unique feature of B. burgdorferi is the large number of nucleotide sequences that it contains for predicted and observed lipoproteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/6\">",
"     6",
"    </a>",
"    ]. Plasmid-encoded antigens include surface-exposed lipoproteins Outer surface protein (Osp) A (31 kDa), OspB (34 kDa) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/9\">",
"     9",
"    </a>",
"    ], OspC (23 kDa) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/10\">",
"     10",
"    </a>",
"    ], the decorin-binding proteins A and B (18 kDa) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/11\">",
"     11",
"    </a>",
"    ], and the VlsE protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/12\">",
"     12",
"    </a>",
"    ]. The spirochete upregulates or downregulates expression of some of these proteins at different times in its life cycle, presumably to suit each environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/13\">",
"     13",
"    </a>",
"    ]. Not all of the proteins are expressed in cultured organisms. For example, VlsE, a major immunogen, is poorly expressed in culture. Therefore, VlsE is produced as a recombinant protein in Escherichia coli for its use for immunodiagnostic assays. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=see_link&amp;anchor=H18#H18\">",
"     \"Diagnosis of Lyme disease\", section on 'Single step VlsE C6 ELISA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=see_link&amp;anchor=H19#H19\">",
"     \"Diagnosis of Lyme disease\", section on 'Addition of a VlsE C6 antigen band to the Western blot of traditional two-tier testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8868578\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Borrelia species do not produce potent toxins, but cause infection by migrating through tissues, disseminating in the blood, adhering to host cells, and evading immune clearance. These properties are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26552?source=see_link\">",
"     \"Immunopathogenesis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data showing that B. burgdorferi has a prolonged intracellular phase in vivo, and no information to suggest that it has an intracellular phase that is not treatable by antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8868658\">",
"    <span class=\"h2\">",
"     Ecologic niche",
"    </span>",
"    &nbsp;&mdash;&nbsp;Borrelia species are obligate parasites; there are no known free-living forms. The spirochetes cycle between two different environments: the tick, a poikilothermic invertebrate without an adaptive immune system, and mammals and birds, homeothermic vertebrates with well-developed adaptive immune systems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology of Lyme disease\", section on 'Tick vectors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology of Lyme disease\", section on 'Reservoir hosts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Borrelia species are microaerophilic and grow optimally in carbon dioxide concentrations typical of the internal milieu of mammals and birds. These bacteria are killed by exposure to temperatures over 50&deg;C for more than a few minutes, hypotonic or hypertonic environments, drying, common disinfectants, such as bleach, and detergents. They are transmitted by ticks, or rarely by direct contact with fresh infected blood or tissues, but not by respiratory secretions, urine, feces, or fomites.",
"   </p>",
"   <p>",
"    In comparison to the larger genomes of most free-living bacteria, the Borrelia genome encodes few proteins with biosynthetic activity. Therefore, Borrelia species depend upon the animal host or the culture medium in the laboratory for most nutritional requirements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8868665\">",
"    <span class=\"h2\">",
"     Protein expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;B. burgdorferi expresses different repertoires of proteins to suit each environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. As an example, to transit from the tick midgut, where the B. burgdorferi are located prior to initiation of feeding, to the tick salivary gland, the organism rapidly downregulates OspA protein and upregulates OspC protein. Downregulation of OspA facilitates detachment from the tick midgut and transit to the salivary glands. Upregulation of OspC facilitates invasion of bacteria into skin, and, in the absence of OspC, bacteria are unable to establish infection in the mammalian host efficiently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26552?source=see_link&amp;anchor=H489178#H489178\">",
"     \"Immunopathogenesis of Lyme disease\", section on 'Outer surface protein variations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although Borrelia species do not produce lipid A-containing endotoxin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/18\">",
"     18",
"    </a>",
"    ], they do produce lipoproteins that are ligands for toll-like receptors on mononuclear blood cells and other cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/19\">",
"     19",
"    </a>",
"    ]. Binding to these receptors can lead to release of pro-inflammatory cytokines with effects qualitatively similar to responses to endotoxin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26552?source=see_link&amp;anchor=H490030#H490030\">",
"     \"Immunopathogenesis of Lyme disease\", section on 'Toll-like receptors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H439683241\">",
"    <span class=\"h2\">",
"     Immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because B. burgdorferi do not secrete toxins, proteases, or other destructive molecules, the majority of the symptoms seen with human Lyme disease are due to the combined effects of the host innate and adaptive immune responses and lytic release of inflammatory bacterial components that follow. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26552?source=see_link\">",
"     \"Immunopathogenesis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H439683379\">",
"    <span class=\"h1\">",
"     DIVERSITY OF BORRELIA SPECIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three species of Borrelia account for most cases of Lyme disease in the world:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B. burgdorferi causes Lyme disease in North America and less extensively in Europe.",
"     </li>",
"     <li>",
"      In Europe and Asia, B. afzelii and B. garinii are the predominant species.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Different species of Ixodes ticks serve as vectors in different regions. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology of Lyme disease\", section on 'Regional distribution'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H439683393\">",
"    <span class=\"h2\">",
"     North America",
"    </span>",
"    &nbsp;&mdash;&nbsp;In eastern North America, the genospecies B. burgdorferi sensu stricto is the principal spirochete circulating in nature and causing Lyme disease in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/20\">",
"     20",
"    </a>",
"    ]. In other areas in which Lyme disease occurs, spirochete populations are more diverse. In far-western North America, I. pacificus can be found infected with B. burgdorferi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/21\">",
"     21",
"    </a>",
"    ]. Human cases of Lyme disease appear to be the result of transmission of B. burgdorferi, but there have been few isolates from humans. An equally prevalent spirochete found in Ixodes ticks in this region is B. bissettii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/22\">",
"     22",
"    </a>",
"    ], but this species has not been established as a cause of human infection or disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H439683400\">",
"    <span class=\"h2\">",
"     Europe and Asia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Europe and Asia, the diversity of Lyme disease spirochetes causing human disease is greater than in North America. In Europe, three genospecies of B. burgdorferi commonly infect humans: B. burgdorferi, B. afzelii, and B. garinii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Some B. burgdorferi strains are found in both North America and Europe, but most strains in Europe are unique to that continent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/25\">",
"     25",
"    </a>",
"    ]. In Asia, B. afzelii and B. garinii are thought to be the most common causes of Lyme disease. However, B. burgdorferi has also been detected from a skin lesion of a patient with Lyme disease in Taiwan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biological differences have been observed among the three predominant Borrelia species, and are likely to be responsible for some of the differences in clinical manifestations in patients in Europe compared with North America. Although all three species have been recovered from various sites in patients, including skin, blood, and cerebrospinal fluid, infection with B. afzelii is associated with a lower risk of neurologic disease than infection with either B. garinii or B. burgdorferi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/1\">",
"     1",
"    </a>",
"    ]. In an in vitro study of representatives of the three species, B. burgdorferi stimulated macrophages to secrete higher levels of cytokines and chemokines than did B. afzelii or B. garinii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/27\">",
"     27",
"    </a>",
"    ]. The clinical differences between Lyme disease in Europe and the United States are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'United States versus Europe'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also differences in the ecology of the species, especially between the two most prevalent species: B. afzelii is mainly associated with rodents as reservoirs, whereas B. garinii is mainly associated with birds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/28\">",
"     28",
"    </a>",
"    ]. This pattern of reservoir hosts for these spirochetes is attributed wholly or in part to relative susceptibility to specific host complement lysis.",
"   </p>",
"   <p>",
"    Unlike North America and western Europe, where most infections are acquired from the bite of a nymphal tick, in Asia and Asian Russia transmission to humans is mainly by the adult stage of the tick [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/29\">",
"     29",
"    </a>",
"    ]. The geographic range of B. afzelii and B. garinii extends to the Pacific coast of Russia and Asia, but the distribution of B. burgdorferi is limited to west of the Ural Mountains.",
"   </p>",
"   <p>",
"    Other Borrelia species, such as B. valaisiana, B. lusitaniae, B. spielmani, and B. bavariensis have been implicated in human disease in Europe or Asia, but frequencies of these species in the tick vectors are generally much lower than those of B. afzelii, B. garinii, and B. burgdorferi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8868418\">",
"    <span class=\"h2\">",
"     Relapsing fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other, more distantly related Borrelia species are the agents of tick-borne and louse-borne relapsing fever, the clinical manifestations of which has little in common with Lyme disease. However, there is sufficient sequence similarity for some proteinaceous antigens of the Lyme disease group of species and the relapsing fever group of species for there to be antigenic cross-reactivity in immunoassays. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39336?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of relapsing fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15033?source=see_link\">",
"     \"Clinical features, diagnosis, and management of relapsing fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H227881830\">",
"    <span class=\"h2\">",
"     Borrelia miyamotoi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Borrelia miyamotoi, a Borrelia species in the same taxonomic group as the agents of relapsing fever, has been found in some of the same tick vectors and rodent reservoirs as for Lyme disease agents in North America, Europe, and Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/30\">",
"     30",
"    </a>",
"    ]. Although B. miyamotoi and the relapsing fever Borrelia species are not established as causes of Lyme disease, several reports have described clinical syndromes in patients with evidence of B. miyamotoi infection. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15033?source=see_link&amp;anchor=H343465099#H343465099\">",
"     \"Clinical features, diagnosis, and management of relapsing fever\", section on 'Borrelia miyamotoi infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H439683075\">",
"    <span class=\"h1\">",
"     RELATIONSHIP OF STRAIN TO CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Lyme disease-endemic regions of North America, there are usually 10 to 15 genetically-distinct strains of B. burgdorferi circulating among wildlife and ticks in a given area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. There are some strains that occur throughout the range of B. burgdorferi in the United States, but other strains have more limited distributions, for instance, occurring in the Midwest but not in the Northeast or the Far West [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/31\">",
"     31",
"    </a>",
"    ]. A similar situation characterizes populations of B. afzelii and B. garinii in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/25\">",
"     25",
"    </a>",
"    ]. Strain typing (genotyping) is achieved by various means; the most common method involves sequencing the ospC gene, a noncoding region of the chromosome, or certain housekeeping genes.",
"   </p>",
"   <p>",
"    Immunity from infection is largely strain-specific. In other words, infection with one strain generally does not confer protection against another strain. Consequently, reinfection of natural hosts and human cases can occur if the newly infecting strain differs from that of the previous infection. The mix of strains in a given area is probably determined by the balance of immune responses of host animals over time, but there may also be strain differences in host associations. These may be determined by the profile of resistance to complement or other serum factors, as was demonstrated for B. afzelii and B. garinii. The lower prevalence of B. burgdorferi in Ixodes ticks in the far-western and southeastern United States has been attributed to the susceptibility of B. burgdorferi to the nonimmune bactericidal effects of serum of lizards, a common host for I. pacificus and I. scapularis ticks in these respective regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/32\">",
"     32",
"    </a>",
"    ]. If an infected tick feeds on a lizard, the blood meal has a sterilizing action.",
"   </p>",
"   <p>",
"    In the northeastern United States, some strains of B. burgdorferi are associated with a higher frequency of disseminated infection in humans than others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Differences between strains in relative frequencies of isolation from skin alone or from the blood correspond to differences between strains in their virulence in laboratory mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42342/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The basis for these strain differences in infections of humans and other mammals is not known. Whether identification of the strain of an infection will be lead to more effective management of the patient has not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342592178\">",
"    <span class=\"h1\">",
"     CULTURE AND STAINING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given their small genome, B. burgdorferi and the other species have few biosynthetic capabilities and require a complex medium and microaerophilic conditions for growth in vitro. Under the best of circumstances, growth is slow, with generation times of six hours or longer. The spirochetes have been isolated from skin, blood, and cerebrospinal fluid, as well as from ticks and various animals, in Barbour-Stoenner-Kelly medium or related formulations. One of the key ingredients in the medium for successful serial passage is N-acetylglucosamine, which is the monomer of chitin, a predominant structural component of the arthropod exoskeleton. The culture medium is available commercially, but few clinical or public health laboratories perform Borrelia cultures.",
"   </p>",
"   <p>",
"    The spirochetes can be visualized with silver stains or by immunofluorescence in biopsies of affected skin, but the numbers of bacteria are low both in skin and in other tissues. The most commonly performed direct detection assay is polymerase chain reaction, but the paucity of organisms in tissues and the disappearance of the organism from the blood within two to four weeks of infection onset limit its utility.",
"   </p>",
"   <p>",
"    The diagnosis of Lyme disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342592214\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lyme disease is the most common tick-borne disease in the United States, Canada, and Europe. It is a bacterial infection caused by members of the Borrelia species, B. burgdorferi in North America, and primarily by B. afzelii and B. garinii in Europe and Asia. (See",
"      <a class=\"local\" href=\"#H1776078715\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The members of Borrelia species are spirochetes, which are motile, spiral, or wavy bacteria that are only distantly related to gram-negative and gram-positive pathogens. The genomes of B. burgdorferi, B. afzelii, and B. garinii comprise small linear chromosomes and linear and circular plasmids. (See",
"      <a class=\"local\" href=\"#H342592157\">",
"       'Classification and genome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Borrelia genome encodes few proteins with biosynthetic activity, and therefore Borrelia species depend upon the host for most nutritional requirements. Borrelia species do not produce toxins, but cause infection by migrating through tissues, adhering to host cells, and evading immune clearance. (See",
"      <a class=\"local\" href=\"#H8868578\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26552?source=see_link\">",
"       \"Immunopathogenesis of Lyme disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Given their small genome, B. burgdorferi and the other species have few biosynthetic capabilities and require a complex medium and microaerophilic conditions for growth in vitro. Under the best of circumstances, growth is slow. The spirochetes have been isolated from skin, blood, and cerebrospinal fluid, as well as from ticks and various animals. The culture medium is available commercially, but few clinical or public health laboratories perform Borrelia cultures. (See",
"      <a class=\"local\" href=\"#H342592178\">",
"       'Culture and staining'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/1\">",
"      Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest 2004; 113:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/2\">",
"      Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 2012; 379:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/3\">",
"      Stanek G, Pletschette M, Flamm H, et al. European Lyme borreliosis. Ann N Y Acad Sci 1988; 539:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/4\">",
"      Steere AC, Malawista SE, Snydman DR, et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. Arthritis Rheum 1977; 20:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/5\">",
"      Burgdorfer W, Barbour AG, Hayes SF, et al. Lyme disease-a tick-borne spirochetosis? Science 1982; 216:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/6\">",
"      Fraser CM, Casjens S, Huang WM, et al. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 1997; 390:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/7\">",
"      Ferdows MS, Barbour AG. Megabase-sized linear DNA in the bacterium Borrelia burgdorferi, the Lyme disease agent. Proc Natl Acad Sci U S A 1989; 86:5969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/8\">",
"      Casjens S, Palmer N, van Vugt R, et al. A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the Lyme disease spirochete Borrelia burgdorferi. Mol Microbiol 2000; 35:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/9\">",
"      Bergstr&ouml;m S, Bundoc VG, Barbour AG. Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Mol Microbiol 1989; 3:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/10\">",
"      Padula SJ, Dias F, Sampieri A, et al. Use of recombinant OspC from Borrelia burgdorferi for serodiagnosis of early Lyme disease. J Clin Microbiol 1994; 32:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/11\">",
"      Guo BP, Norris SJ, Rosenberg LC, H&ouml;&ouml;k M. Adherence of Borrelia burgdorferi to the proteoglycan decorin. Infect Immun 1995; 63:3467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/12\">",
"      Zhang JR, Hardham JM, Barbour AG, Norris SJ. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell 1997; 89:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/13\">",
"      Schwan TG, Piesman J, Golde WT, et al. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc Natl Acad Sci U S A 1995; 92:2909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/14\">",
"      Margolis N, Rosa PA. Regulation of expression of major outer surface proteins in Borrelia burgdorferi. Infect Immun 1993; 61:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/15\">",
"      de Silva AM, Fikrig E. Arthropod- and host-specific gene expression by Borrelia burgdorferi. J Clin Invest 1997; 99:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/16\">",
"      Tilly K, Bestor A, Dulebohn DP, Rosa PA. OspC-independent infection and dissemination by host-adapted Borrelia burgdorferi. Infect Immun 2009; 77:2672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/17\">",
"      Tilly K, Krum JG, Bestor A, et al. Borrelia burgdorferi OspC protein required exclusively in a crucial early stage of mammalian infection. Infect Immun 2006; 74:3554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/18\">",
"      Takayama K, Rothenberg RJ, Barbour AG. Absence of lipopolysaccharide in the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 1987; 55:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/19\">",
"      Hirschfeld M, Kirschning CJ, Schwandner R, et al. Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J Immunol 1999; 163:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/20\">",
"      Hoen AG, Margos G, Bent SJ, et al. Phylogeography of Borrelia burgdorferi in the eastern United States reflects multiple independent Lyme disease emergence events. Proc Natl Acad Sci U S A 2009; 106:15013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/21\">",
"      Girard YA, Travinsky B, Schotthoefer A, et al. Population structure of the lyme borreliosis spirochete Borrelia burgdorferi in the western black-legged tick (Ixodes pacificus) in Northern California. Appl Environ Microbiol 2009; 75:7243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/22\">",
"      Brown RN, Peot MA, Lane RS. Sylvatic maintenance of Borrelia burgdorferi (Spirochaetales) in Northern California: untangling the web of transmission. J Med Entomol 2006; 43:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/23\">",
"      Baranton G, Postic D, Saint Girons I, et al. Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis. Int J Syst Bacteriol 1992; 42:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/24\">",
"      Baranton G, De Martino SJ. Borrelia burgdorferi sensu lato diversity and its influence on pathogenicity in humans. Curr Probl Dermatol 2009; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/25\">",
"      Bunikis J, Garpmo U, Tsao J, et al. Sequence typing reveals extensive strain diversity of the Lyme borreliosis agents Borrelia burgdorferi in North America and Borrelia afzelii in Europe. Microbiology 2004; 150:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/26\">",
"      Chao LL, Chen YJ, Shih CM. First isolation and molecular identification of Borrelia burgdorferi sensu stricto and Borrelia afzelii from skin biopsies of patients in Taiwan. Int J Infect Dis 2011; 15:e182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/27\">",
"      Strle K, Drouin EE, Shen S, et al. Borrelia burgdorferi stimulates macrophages to secrete higher levels of cytokines and chemokines than Borrelia afzelii or Borrelia garinii. J Infect Dis 2009; 200:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/28\">",
"      Kurtenbach K, De Michelis S, Etti S, et al. Host association of Borrelia burgdorferi sensu lato--the key role of host complement. Trends Microbiol 2002; 10:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/29\">",
"      Korenberg EI. Comparative ecology and epidemiology of lyme disease and tick-borne encephalitis in the former Soviet Union. Parasitol Today 1994; 10:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/30\">",
"      Barbour AG, Bunikis J, Travinsky B, et al. Niche partitioning of Borrelia burgdorferi and Borrelia miyamotoi in the same tick vector and mammalian reservoir species. Am J Trop Med Hyg 2009; 81:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/31\">",
"      Barbour AG, Travinsky B. Evolution and distribution of the ospC Gene, a transferable serotype determinant of Borrelia burgdorferi. MBio 2010; 1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/32\">",
"      Lane RS, Quistad GB. Borreliacidal factor in the blood of the western fence lizard (Sceloporus occidentalis). J Parasitol 1998; 84:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/33\">",
"      Wormser GP, Brisson D, Liveris D, et al. Borrelia burgdorferi genotype predicts the capacity for hematogenous dissemination during early Lyme disease. J Infect Dis 2008; 198:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/34\">",
"      Jones KL, Glickstein LJ, Damle N, et al. Borrelia burgdorferi genetic markers and disseminated disease in patients with early Lyme disease. J Clin Microbiol 2006; 44:4407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/35\">",
"      Seinost G, Dykhuizen DE, Dattwyler RJ, et al. Four clones of Borrelia burgdorferi sensu stricto cause invasive infection in humans. Infect Immun 1999; 67:3518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/36\">",
"      Liveris D, Varde S, Iyer R, et al. Genetic diversity of Borrelia burgdorferi in lyme disease patients as determined by culture versus direct PCR with clinical specimens. J Clin Microbiol 1999; 37:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/37\">",
"      Wang G, Ojaimi C, Wu H, et al. Disease severity in a murine model of lyme borreliosis is associated with the genotype of the infecting Borrelia burgdorferi sensu stricto strain. J Infect Dis 2002; 186:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42342/abstract/38\">",
"      Hanincov&aacute; K, Ogden NH, Diuk-Wasser M, et al. Fitness variation of Borrelia burgdorferi sensu stricto strains in mice. Appl Environ Microbiol 2008; 74:153.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16138 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-9F549ED38C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42342=[""].join("\n");
var outline_f41_22_42342=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H342592214\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1776078715\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H342592157\">",
"      CLASSIFICATION AND GENOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H342592788\">",
"      BORRELIA PROTEINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8868578\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8868658\">",
"      Ecologic niche",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8868665\">",
"      Protein expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H439683241\">",
"      Immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H439683379\">",
"      DIVERSITY OF BORRELIA SPECIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H439683393\">",
"      North America",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H439683400\">",
"      Europe and Asia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8868418\">",
"      Relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H227881830\">",
"      Borrelia miyamotoi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H439683075\">",
"      RELATIONSHIP OF STRAIN TO CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H342592178\">",
"      CULTURE AND STAINING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H342592214\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15033?source=related_link\">",
"      Clinical features, diagnosis, and management of relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26263?source=related_link\">",
"      Evaluation of a tick bite for possible Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26552?source=related_link\">",
"      Immunopathogenesis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7225?source=related_link\">",
"      Lyme disease: Clinical manifestations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39336?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3960?source=related_link\">",
"      Prevention of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_22_42343="Management of significant proximal left anterior descending coronary artery disease";
var content_f41_22_42343=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of significant proximal left anterior descending coronary artery disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/22/42343/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/22/42343/contributors\">",
"     Malcolm R Bell, MBBS, FRACP, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/22/42343/contributors\">",
"     John A Bittl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/22/42343/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/22/42343/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/22/42343/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/22/42343/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/22/42343/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/22/42343/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with coronary artery disease (CAD) is related to the extent of myocardium at risk. Proximal left anterior descending coronary artery (LAD) lesions often supply a high percentage of the left ventricular myocardium, compared to proximal lesions in the circumflex or right coronary arteries.",
"   </p>",
"   <p>",
"    This topic will discuss both the choice between medical therapy and revascularization for treatment of proximal LAD disease in stable patients as well as the choice between coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) in those patients in whom revascularization is chosen. This discussion will focus on the outcomes of survival, myocardial infarction (MI), and revascularization rates. Revascularization to improve angina refractory to medical therapy in patients for whom survival will not be improved is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with stable, nonproximal LAD disease is similar to disease identified in the circumflex and right coronary arteries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discussion of coronary artery revascularization in the large subgroup of patients with diabetes is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=see_link\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62852894\">",
"    <span class=\"h1\">",
"     DEFINITION OF SIGNIFICANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the purposes of this topic, significant disease of the proximal (proximal to and including the first major septal branch) left anterior descending coronary artery is present when coronary angiography reveals one or more obstructive lesions and one of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angina pectoris that is reasonably attributed to the lesion(s). Usually, the visual estimate of the severity of the stenosis is 70 percent or greater luminal narrowing.",
"     </li>",
"     <li>",
"      A stress test, with or without imaging, showing evidence of moderate to severe myocardial ischemia consistent with a proximal LAD lesion.",
"     </li>",
"     <li>",
"      Physiologic evidence at the time of cardiac catheterization supporting the finding of a significant lesion, such as an abnormal (low) fractional flow reserve. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13672?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical use of coronary artery pressure and Doppler flow measurements\", section on 'Clinical use of translesional physiologic measurements'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H537238890\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT OF CORONARY ARTERY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with CAD should have their risk of subsequent cardiovascular events assessed with stress testing and some should have evaluation of left ventricular systolic function. All patients require aggressive risk-factor reduction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=see_link&amp;anchor=H94290458#H94290458\">",
"     \"Overview of the care of patients with stable ischemic heart disease\", section on 'Measurement of LV systolic function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REVASCULARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with significant proximal LAD disease who have angina refractory to medical therapy, revascularization should be considered to improve symptoms. In addition, revascularization should be preferred to medical therapy in many such patients who have certain high-risk predictors, such as a large amount of viable myocardium at risk as determined by stress testing with or without noninvasive imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] or significant underlying left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Virtually all patients with a significant proximal LAD lesion, with or without multivessel disease, will fall into one of these two groups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\", section on 'Effects on survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no contemporary randomized trials specifically comparing revascularization to medical therapy in stable patients with isolated proximal LAD disease. Thus, recommendations are based on extrapolation from trials comparing medical therapy with revascularization in broader populations, such as those with multivessel disease and a large area of myocardium at risk or significant underlying left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. In these populations, worse outcomes have been found with medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\", section on 'Effects on survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two studies suggesting benefit from revascularization are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a retrospective analysis of 1188 patients with one vessel, proximal LAD disease who were followed for a median of 5.7 years after initial treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/6\">",
"       6",
"      </a>",
"      ], CABG using the left internal mammary artery was associated with a significant reduction in the composite end point of freedom from death, myocardial infarction, or the need for repeat procedures compared to medical therapy (hazard ratio 0.48, 95% CI 0.23-0.64), but no significant improvement in adjusted survival (hazard ratio 0.74, 95% CI 0.44-1.23) at more than one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a 1994 meta-analysis of trials comparing medical and surgical therapy in patients with stable coronary disease, 59 percent of randomized patients had significant disease of the proximal LAD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/3\">",
"       3",
"      </a>",
"      ]. Among patients with one or two vessel disease, including the proximal LAD, CABG was associated with a significant reduction in five-year mortality (9 versus 15 percent with medical therapy, odds ratio 0.58). In comparison, patients with one or two vessel disease without proximal LAD involvement did equally well with medical therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another trial using contemporary medical therapy, COURAGE, included a small group of patients with isolated proximal LAD disease. In COURAGE, which excluded patients with severe angina, a markedly positive treadmill test (significant ST-segment depressions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a hypotensive blood pressure response during stage I of the Bruce protocol) and a left ventricular ejection fraction of less than 30 percent, there was no significant difference between aggressive medical therapy or aggressive medical therapy plus PCI with bare metal stenting. Because COURAGE excluded many patients with proximal LAD disease with a large area of myocardium at risk, we do not believe its conclusions apply. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link&amp;anchor=H13#H13\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\", section on 'COURAGE and FAME II trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85278848\">",
"    <span class=\"h2\">",
"     Patients with prior CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on our clinical experience, rather than evidence from randomized trials or observational studies, we and others suggest repeat revascularization in patients with prior coronary artery bypass graft surgery (CABG) and new obstruction of the proximal LAD artery with extensive anterior ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In these patients, survival is likely to be better with revascularization. For patients without prior placement of a left internal thoracic artery, CABG is preferred to PCI.",
"   </p>",
"   <p>",
"    Patients with ischemia in other locations and those with a patent LIMA to the LAD artery are unlikely to experience a survival benefit from repeat revascularization and the decision to revascularize should be made primarily on the basis of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link&amp;anchor=H15#H15\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\", section on 'Both PCI and CABG versus medical therapy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PCI VERSUS CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those patients in whom revascularization is chosen, the choice between percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG) depends on clinical parameters as well as the patient&rsquo;s preference for the potential burdens associated with each form of revascularization. We prefer PCI with stenting in many patients with less complex coronary artery disease and relatively well preserved left ventricular systolic function. CABG might be preferred to PCI in patients with complex, proximal LAD disease with other unfavorable lesions (eg, chronic total occlusion in another vessel). Other patient and angiographic characteristics also may affect the decision such as age, left ventricular dysfunction, and diabetes mellitus (in which the outcome may be better with CABG). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=see_link&amp;anchor=H24#H24\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'PCI versus CABG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial studies compared CABG to percutaneous transluminal coronary angioplasty (PTCA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/10-19\">",
"     10-19",
"    </a>",
"    ]. Long-term survival was similar but revascularization rates were higher with PTCA compared to CABG in the broad group of patients with multivessel disease. However, PTCA without stenting is now rarely performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PCI can usually be performed with a high chance of success and low risk of complications in proximal LAD disease. When faced with more complex lesions such as true ostial location, particularly with involvement of the distal left main coronary artery, adjacent circumflex ostial disease, or complex bifurcation lesions involving a large first diagonal branch, consideration of CABG should be made. Complex LAD-diagonal bifurcation lesions and ostial LAD lesions that are flush with the distal left main should only be attempted by highly experienced operators in institutions with cardiac surgical facilities. When percutaneous coronary intervention (PCI) with stenting is performed, drug-eluting stents (DES) are preferred in most patients because of a marked reduction in the incidence of restenosis compared to bare metal stents (BMS), including patients with proximal LAD disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1081?source=see_link\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patients with multivessel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer CABG rather than PCI for many patients with a significant narrowing of the proximal LAD with multivessel disease who have a reduced left ventricular ejection fraction or a large area of myocardium at risk. Earlier stent versus CABG trials in patients with multivessel disease including the proximal LAD have shown similar long-term survival, but higher rates of repeat target vessel revascularization with stents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/23-28\">",
"     23-28",
"    </a>",
"    ]. Few of these patients in these trials had a left ventricular ejection fraction &lt;30 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=see_link&amp;anchor=H11#H11\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'Stenting versus CABG for multivessel disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/22/17770?source=see_link&amp;anchor=H4#H4\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Left main and left anterior descending disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For example, the SYNTAX trial randomly assigned 1800 patients with three-vessel or left main coronary artery disease to either CABG or PCI with DES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/29\">",
"     29",
"    </a>",
"    ]. After 12 months of follow-up, the composite primary end point (death from any cause, stroke, MI, or repeat revascularization) was significantly higher in the PCI group (17.8 versus 12.4 percent), with the result driven primarily by more frequent revascularization with PCI (13.5 versus 5.9 percent). After five years, however, CABG was also associated with fewer MI and the lower rate of the composite outcome of death, stroke, or MI. This trial is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=see_link&amp;anchor=H17#H17\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'SYNTAX trial'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Patients with lower SYNTAX scores had lower event rates than those with intermediate or high scores. Secondary analyses suggested that among patients with low SYNTAX scores, the clinical outcomes were comparable with PCI and CABG, whereas in patients with higher SYNTAX score outcomes were better with CABG. The SYNTAX score predicts a higher long-term risk with proximal LAD disease than with either proximal circumflex or right coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link&amp;anchor=H468900345#H468900345\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'SYNTAX score and SYNTAX score II'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the ability of these trials comparing PCI with CABG are somewhat limited in their ability to guide decision making in patients with proximal LAD disease as they included relatively few patients with these lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H468899215\">",
"    <span class=\"h2\">",
"     Patients with single vessel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with significant",
"    <strong>",
"     single vessel",
"    </strong>",
"    , proximal LAD disease in whom revascularization has been recommended, we suggest PCI rather than CABG. This preference is based on the desire to avoid the potential complications of CABG (such as stroke) despite a higher rate of repeat revascularization with PCI, particularly when bare metal stents are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/17,30\">",
"     17,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We estimate that an isolated proximal stenosis of the LAD is found in about 2 to 4 percent of patients undergoing diagnostic angiography. As discussed above, this finding is sometimes, but not always, an absolute indication for revascularization, since clinical trials have not shown a survival benefit compared to medical therapy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Indications for revascularization'",
"    </a>",
"    above.) Thus, the main indication for intervention in this setting is for symptoms due to failure of medical therapy. However, given the safety and low procedural morbidity associated with PCI and stenting, most cardiologists favor revascularization of the proximal LAD given the large area at risk. &nbsp;",
"   </p>",
"   <p>",
"    A 2008 meta-analysis of nine randomized trials, including 1210 patients, found no five- or ten-year survival difference between CABG and PCI for management of single vessel LAD disease, although rates of repeat revascularization were higher at five years with PCI (33.5 versus 7.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/31\">",
"     31",
"    </a>",
"    ]. A second meta-analysis came to similar conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trials using a lateral or anterolateral thoracotomy (MID CABG) in patients with isolated LAD stenosis have suggested that this surgical approach is associated with equivalent mortality but better symptom control and a lower rate of target vessel revascularization than percutaneous coronary intervention (PCI) with bare metal stents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial comparing PCI with DES to minimally invasive direct coronary artery bypass surgery (MIDCAB) evaluated outcomes in 130 patients with isolated proximal LAD disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/36\">",
"     36",
"    </a>",
"    ]. The primary clinical endpoint was freedom from death, myocardial infarction, or the need for target vessel revascularization. At one year, PCI with DES was noninferior to MIDCAB, with an event rate of 7.7 percent in both groups. Patients who received PCI had a higher rate of revascularization (6.2 versus 0 percent), while those who received MIDCAB had a higher rate of MI (7.7 versus 1.5 percent), most of which was periprocedural. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=see_link&amp;anchor=H3#H3\">",
"     \"Early cardiac complications of coronary artery bypass graft surgery\", section on 'Perioperative MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the patient with severe single vessel disease involving only the proximal LAD, it is important for the patient to be made aware of the strengths and weakness of either approach. For patients with more complex lesions, such as ostial location, diffuse disease, or bifurcation lesions, the risks with PCI increase. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link&amp;anchor=H468900345#H468900345\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'SYNTAX score and SYNTAX score II'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following guidelines include recommendations for the management of patients with proximal LAD disease. Recommendations made in these guidelines do not differ significantly from those made in this topic review, except as noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      2011 American College of Cardiology",
"      <span class=\"nowrap\">",
"       Foundation/American",
"      </span>",
"      Heart",
"      <span class=\"nowrap\">",
"       Association/Society",
"      </span>",
"      of Cardiovascular Angiography and Intervention guideline for percutaneous coronary intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      2011 American College of Cardiology",
"      <span class=\"nowrap\">",
"       Foundation/American",
"      </span>",
"      Heart Association guideline for coronary artery bypass graft surgery (CABG) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      2010 European Society of Cardiology guidelines on myocardial revascularization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42343/abstract/39\">",
"       39",
"      </a>",
"      ]. This document recommends revascularization to improve prognosis for significant proximal LAD disease, which is defined as any lesion with &gt;50 percent stenosis and documented ischemia or fractional flow reserve &le;0.80 for angiographic diameter stenoses 50 to 90 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The general approach to patients with proximal left anterior descending coronary artery (LAD) disease is similar to that of all patients with coronary heart disease. This should include appropriate secondary prevention strategies and risk stratification as well as the use of revascularization in patients with angina refractory to medical therapy. (See",
"      <a class=\"local\" href=\"#H537238890\">",
"       'General management of coronary artery disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications for revascularization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a significant narrowing of the proximal LAD who have high-risk criteria (left ventricular ejection fraction &lt;30 percent or evidence of a large area of potentially ischemic myocardium), regardless of anginal severity, we recommend revascularization rather than medical therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications for revascularization'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients without these high risk predictors, we suggest revascularization rather than medical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our preference for revascularization increases as the left ventricular ejection fraction falls or as the extent of myocardium at risk increases.",
"     </li>",
"     <li>",
"      For patients with a significant narrowing of the proximal LAD with",
"      <strong>",
"       multivessel",
"      </strong>",
"      CAD who have a moderately reduced left ventricular ejection fraction (LVEF) of 30 to 50 percent or a large area of myocardium at risk, we suggest CABG rather than PCI (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For these patients with multivessel disease who have a LVEF &lt;30 percent, we suggest CABG rather than PCI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients without these high risk predictors, PCI is a reasonable option. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Patients with multivessel disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with significant",
"      <strong>",
"       single vessel",
"      </strong>",
"      , proximal LAD disease in whom revascularization has been recommended, we suggest PCI rather than CABG (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, for those patients who prefer to accept the higher early morbidity (including an increased risk of stroke) with CABG, in exchange for a lower rate of subsequent revascularization, CABG is an appropriate strategy. (See",
"      <a class=\"local\" href=\"#H468899215\">",
"       'Patients with single vessel disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients in whom a decision has been made to perform revascularization, it should be kept in mind that not all proximal lesions carry the same prognosis or success rate with percutaneous coronary intervention (PCI). This information may influence decision making between PCI and CABG. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/1\">",
"      Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003; 107:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/2\">",
"      Tarakji KG, Brunken R, McCarthy PM, et al. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation 2006; 113:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/3\">",
"      Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/4\">",
"      Alderman EL, Fisher LD, Litwin P, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983; 68:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/5\">",
"      O'Connor CM, Velazquez EJ, Gardner LH, et al. Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). Am J Cardiol 2002; 90:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/6\">",
"      Greenbaum AB, Califf RM, Jones RH, et al. Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending coronary artery disease. Am J Cardiol 2000; 86:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/7\">",
"      Brener SJ, Lytle BW, Casserly IP, et al. Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Heart J 2006; 27:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/8\">",
"      Lytle BW, Loop FD, Taylor PC, et al. The effect of coronary reoperation on the survival of patients with stenoses in saphenous vein bypass grafts to coronary arteries. J Thorac Cardiovasc Surg 1993; 105:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/9\">",
"      Subramanian S, Sabik JF 3rd, Houghtaling PL, et al. Decision-making for patients with patent left internal thoracic artery grafts to left anterior descending. Ann Thorac Surg 2009; 87:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/10\">",
"      Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet 1993; 341:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/11\">",
"      Rodriguez A, Boullon F, Perez-Bali&ntilde;o N, et al. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group. J Am Coll Cardiol 1993; 22:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/12\">",
"      Hamm CW, Reimers J, Ischinger T, et al. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med 1994; 331:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/13\">",
"      King SB 3rd, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 1994; 331:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/14\">",
"      First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. Lancet 1995; 346:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/15\">",
"      Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996; 335:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/16\">",
"      Pocock SJ, Henderson RA, Rickards AF, et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet 1995; 346:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/17\">",
"      Goy JJ, Kaufmann U, Goy-Eggenberger D, et al. A prospective randomized trial comparing stenting to internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: the SIMA trial. Stenting vs Internal Mammary Artery. Mayo Clin Proc 2000; 75:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/18\">",
"      Goy JJ, Eeckhout E, Burnand B, et al. Coronary angioplasty versus left internal mammary artery grafting for isolated proximal left anterior descending artery stenosis. Lancet 1994; 343:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/19\">",
"      Goy JJ, Eeckhout E, Moret C, et al. Five-year outcome in patients with isolated proximal left anterior descending coronary artery stenosis treated by angioplasty or left internal mammary artery grafting. A prospective trial. Circulation 1999; 99:3255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/20\">",
"      Sawhney N, Moses JW, Leon MB, et al. Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. Circulation 2004; 110:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/21\">",
"      Dangas G, Ellis SG, Shlofmitz R, et al. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. J Am Coll Cardiol 2005; 45:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/22\">",
"      Seung KB, Kim YH, Park DW, et al. Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance. J Am Coll Cardiol 2005; 46:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/23\">",
"      Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/24\">",
"      Bhatt DL, Topol EJ. Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fight. Curr Control Trials Cardiovasc Med 2001; 2:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/25\">",
"      Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005; 352:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/26\">",
"      Rodriguez A, Rodr&iacute;guez Alemparte M, Baldi J, et al. Coronary stenting versus coronary bypass surgery in patients with multiple vessel disease and significant proximal LAD stenosis: results from the ERACI II study. Heart 2003; 89:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/27\">",
"      Aoki J, Ong AT, Arampatzis CA, et al. Comparison of three-year outcomes after coronary stenting versus coronary artery bypass grafting in patients with multivessel coronary disease, including involvement of the left anterior descending coronary artery proximally (a subanalysis of the arterial revascularization therapies study trial). Am J Cardiol 2004; 94:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/28\">",
"      Kukreja N, Serruys PW, De BRUYNE B, et al. Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior desceniding artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS II). Heart 2009; [Epub ahead of print].",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/29\">",
"      Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/30\">",
"      Goy JJ, Kaufmann U, Hurni M, et al. 10-year follow-up of a prospective randomized trial comparing bare-metal stenting with internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis the SIMA (Stenting versus Internal Mammary Artery grafting) trial. J Am Coll Cardiol 2008; 52:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/31\">",
"      Kapoor JR, Gienger AL, Ardehali R, et al. Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. JACC Cardiovasc Interv 2008; 1:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/32\">",
"      Aziz O, Rao C, Panesar SS, et al. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ 2007; 334:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/33\">",
"      Diegeler A, Thiele H, Falk V, et al. Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. N Engl J Med 2002; 347:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/34\">",
"      Drenth DJ, Veeger NJ, Winter JB, et al. A prospective randomized trial comparing stenting with off-pump coronary surgery for high-grade stenosis in the proximal left anterior descending coronary artery: three-year follow-up. J Am Coll Cardiol 2002; 40:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/35\">",
"      Thiele H, Oettel S, Jacobs S, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: a 5-year follow-up. Circulation 2005; 112:3445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/36\">",
"      Thiele H, Neumann-Schniedewind P, Jacobs S, et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. J Am Coll Cardiol 2009; 53:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/37\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58:e44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/38\">",
"      Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42343/abstract/39\">",
"      Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31:2501.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1544 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-BC92F1AF1C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42343=[""].join("\n");
var outline_f41_22_42343=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62852894\">",
"      DEFINITION OF SIGNIFICANT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H537238890\">",
"      GENERAL MANAGEMENT OF CORONARY ARTERY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS FOR REVASCULARIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85278848\">",
"      Patients with prior CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PCI VERSUS CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patients with multivessel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H468899215\">",
"      Patients with single vessel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13672?source=related_link\">",
"      Clinical use of coronary artery pressure and Doppler flow measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1081?source=related_link\">",
"      Drug-eluting compared to bare metal intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=related_link\">",
"      Early cardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/58/2986?source=related_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/22/17770?source=related_link\">",
"      Use of intracoronary stents for specific coronary lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_22_42344="Hysterosalpingogram a";
var content_f41_22_42344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68677%7EOBGYN%2F63310%7EOBGYN%2F76139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68677%7EOBGYN%2F63310%7EOBGYN%2F76139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Hysterosalpingogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hysterosalpingogram on a 29-year-old woman with infertility demonstrates occlusion of both fallopian tubes (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelvic fluoroscopic image",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pelvic fluoroscopic image during fallopian tube recanalization shows a guidewire and microcatheter passed through the left fallopian tube.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Tubal recanalization C",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Widely patent both fallopian tubes (arrows) shown with free spillage of contrast medium into the pelvic intraperitoneal space following the fallopian tube recanalization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42344=[""].join("\n");
var outline_f41_22_42344=null;
var title_f41_22_42345="Hemisected male pelvis and perineum";
var content_f41_22_42345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    Hemisected male pelvis and perineum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF, Agur AR. Pelvis and Perineum. In: Clinically Oriented Anatomy, 6th ed, Lippincott Williams &amp; Wilkins, New York 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42345=[""].join("\n");
var outline_f41_22_42345=null;
var title_f41_22_42346="Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer";
var content_f41_22_42346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/22/42346/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/22/42346/contributors\">",
"     Christopher G Willett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/22/42346/contributors\">",
"     David P Ryan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/22/42346/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/22/42346/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/22/42346/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/22/42346/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/22/42346/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annually, approximately 40,340 patients are diagnosed with rectal cancer in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/1\">",
"     1",
"    </a>",
"    ]. Global incidence data are available from the World Health Organization",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/\">",
"     Globocan database",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Surgical resection is the cornerstone of curative treatment. Superficially invasive, small cancers may be effectively managed with limited surgical procedures, such as local excision. However, the majority of patients have more deeply invasive tumors that require more extensive surgery, such as low anterior or abdominoperineal resection. Others present with locally advanced tumors that are adherent or fixed to adjoining structures such as the sacrum, pelvic sidewalls, prostate, or bladder. The surgical and oncologic management of these patients varies greatly depending upon stage and location within the rectum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=see_link\">",
"     \"Pretreatment local staging evaluation for rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87588997#H87588997\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Criteria for operative procedures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38137?source=see_link\">",
"     \"Overview of surgical procedures for resectable primary rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/37/11866?source=see_link\">",
"     \"Treatment of locally advanced unresectable or recurrent rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tumors in the upper and middle rectum can usually be managed with low anterior resection (LAR), coloanal anastomosis, and preservation of the anal sphincter. Although the resulting anorectal function may be imperfect, the risk of postoperative sexual and urinary dysfunction may be diminished by preservation of the pelvic autonomic nerves. This is possible in most cases, particularly with the use of total mesorectal excision (TME) (",
"    <a class=\"graphic graphic_figure graphicRef65765 \" href=\"mobipreview.htm?35/11/36020\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The avoidance of a permanent colostomy is a major benefit. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87590296#H87590296\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Total mesorectal excision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of cancers in the lower rectum (ie, tumors within 5 cm of the anal verge (",
"    <a class=\"graphic graphic_figure graphicRef62539 \" href=\"mobipreview.htm?14/30/14819\">",
"     figure 2",
"    </a>",
"    )) poses major challenges in terms of local tumor control and preservation of the anal sphincter. Abdominoperineal resection (APR) has long been considered to be the standard operation for lower rectal tumors with a distal edge up to 6 cm from the anal verge. However, despite providing excellent local control and survival, the APR entails a permanent colostomy and a high incidence of sexual and urinary dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38137?source=see_link&amp;anchor=H87595450#H87595450\">",
"     \"Overview of surgical procedures for resectable primary rectal cancer\", section on 'Abdominal perineal resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sphincter-sparing approaches for lower rectal cancers have evolved along two pathways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with small rectal cancers that are confined to the rectal wall (T1 or T2, (",
"      <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"       table 1",
"      </a>",
"      )), local excision techniques may offer local control and survival rates that are comparable to APR, while preserving sphincter function. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38137?source=see_link&amp;anchor=H87594804#H87594804\">",
"       \"Overview of surgical procedures for resectable primary rectal cancer\", section on 'Local excision'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with larger or more invasive tumors, preoperative (neoadjuvant) radiation therapy (RT) and chemoradiotherapy have been utilized to promote tumor regression in an attempt to convert a planned APR to a sphincter-sparing surgical procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will discuss neoadjuvant approaches for sphincter preservation in patients with rectal cancer. Clinical manifestations, diagnosis and pretreatment staging, surgical management, postoperative adjuvant therapy, and posttreatment follow-up surveillance are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=see_link\">",
"     \"Pretreatment local staging evaluation for rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38137?source=see_link\">",
"     \"Overview of surgical procedures for resectable primary rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link\">",
"     \"Surveillance after colorectal cancer resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR NEOADJUVANT TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant chemoradiotherapy is generally considered in the following circumstances:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     T3/4 tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only definitive indication for neoadjuvant chemoradiotherapy, supported by the results of randomized trials, is the presence of T3 or T4 rectal cancer (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ). These are patients who, if resected initially, would likely require postoperative RT. Data from randomized trials suggest that the preoperative approach is associated with a more favorable long-term toxicity profile and fewer local recurrences than postoperative therapy. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Versus adjuvant chemoradiotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H629501194\">",
"    <span class=\"h3\">",
"     cT3N0 tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of clinical T3N0 rectal cancer (cT3N0 based upon preoperative transrectal ultrasound [TRUS]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI) is unclear. Some of these patients have a sufficiently favorable prognosis that questions have been raised as to the necessity of postoperative adjuvant therapy after upfront total mesorectal excision. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link&amp;anchor=H20#H20\">",
"     \"Adjuvant therapy for resected rectal cancer\", section on 'Favorable risk rectal cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Others have questioned the utility of upfront chemoradiotherapy for patients with cT3N0 tumors, particularly those involving the upper rectum, given the favorable low rates of local recurrence after TME alone in the Dutch TME trial and retrospective analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Short-course, Swedish style RT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    On the other hand, as many as one-fifth of these patients may be understaged by preoperative imaging. In a review of 188 patients with",
"    <span class=\"nowrap\">",
"     TRUS/MRI",
"    </span>",
"    staged T3N0 rectal cancer patients who received preoperative chemoradiotherapy, 41 (22 percent) were found to have pathologically positive mesorectal lymph nodes at the time of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/10\">",
"     10",
"    </a>",
"    ]. Given the downstaging effect of chemoradiotherapy, it is likely that an even larger number of these patients would have been found to have node-positive disease (and recommended for postoperative adjuvant therapy) had surgery been undertaken initially.",
"   </p>",
"   <p>",
"    Thus, given the limitations of current imaging, all patients with cT3N0 rectal cancer by TRUS or MRI could be considered appropriate candidates for neoadjuvant chemoradiotherapy.",
"   </p>",
"   <p>",
"    Issues related to locoregional staging in patients with newly diagnosed rectal cancer are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=see_link\">",
"     \"Pretreatment local staging evaluation for rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1109524\">",
"    <span class=\"h3\">",
"     Contribution of depth of extramural penetration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have shown that T3 tumors with &gt;5mm of extramural invasion have a higher rate of nodal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/11\">",
"     11",
"    </a>",
"    ] and lower cancer-specific survival (54 versus 85 percent in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/12\">",
"     12",
"    </a>",
"    ]) compared to tumors with a depth of penetration of 5 mm or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/12\">",
"     12",
"    </a>",
"    ]. These findings have led some to suggest that it is not necessarily the distinction between T2 and T3 tumors that may potentially govern treatment decisions but the identification of high-risk T3 tumors with a &gt;5mm depth of extramural tumor invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    While preoperative high-resolution MRI can identify those patients with T3 tumors and &gt;5mm of extramural tumor invasion, and some data from the MERCURY trial suggest that these patients may have a good outcome with surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/14\">",
"     14",
"    </a>",
"    ], the approach of selecting patients with T3 rectal tumors for preoperative therapy based upon the depth of extramural tumor invasion is not yet standard, at least in the US. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=see_link&amp;anchor=H10#H10\">",
"     \"Pretreatment local staging evaluation for rectal cancer\", section on 'MRI scan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Relative indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relative indications for neoadjuvant chemoradiotherapy include the presence of clinically node-positive rectal cancer in a patient with an MRI or TRUS-staged",
"    <span class=\"nowrap\">",
"     T1/2",
"    </span>",
"    rectal cancer, a distal rectal tumor for which an APR is thought to be necessary, and a tumor which appears to invade the mesorectal fascia on preoperative imaging, because of the decreased likelihood of achieving a tumor-free circumferential resection margin with upfront surgery.",
"   </p>",
"   <p>",
"    For all of these clinical situations, conclusive evidence to support benefit for preoperative chemoradiotherapy is lacking. Furthermore, in many of these situations, postoperative therapy (radiotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy) may not be indicated based upon the final pathology report if the patient were to undergo initial surgery. The decision to use neoadjuvant chemoradiotherapy commits the treating team to a four to six month course of postoperative adjuvant chemotherapy. This is because of the significant downstaging that occurs with chemoradiotherapy. Patients who are found to have negative nodes following chemoradiation may have been positive at presentation, and the presence of positive nodes is a marker for an increased risk of systemic recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     T1/2 and clinically node-positive",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have T1 or T2 tumors (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) and a suspicion of node-positive disease by MRI or TRUS, the determination of \"node positivity\" can be difficult. Most lymph nodes involved by rectal cancer are less than 1 cm, but not all lymph nodes seen by MRI or TRUS represent metastatic disease. MRI can assist in the determination of whether small visualized nodes are likely to be malignant by detecting mixed intranodal signal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    irregularity of the border. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=see_link&amp;anchor=H6103151#H6103151\">",
"     \"Pretreatment local staging evaluation for rectal cancer\", section on 'Assessing T and N stage, and the status of the CRM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neoadjuvant chemoradiotherapy might be considered an appropriate option for these patients if they had involved lymph nodes. Thus, careful consideration for biopsy should be given to any patient who has a clinical T1 or T2 tumor and questionable perirectal lymph nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Distal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with distal rectal tumors, a major goal of preoperative therapy is to convert the surgical procedure from an APR to a sphincter-preserving operation, such as an LAR with coloanal anastomosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. Whether or not an APR is required is somewhat subjective, and this makes determining this particular benefit of neoadjuvant therapy difficult to quantify, at least in terms of sphincter preservation. Sphincter preservation rates are highly dependent on the skill and experience of the surgeon, factors that are difficult to document.",
"   </p>",
"   <p>",
"    The most common method to determine if preoperative therapy has increased the rate of sphincter preservation is through clinical assessment, in which the operating surgeon examines the patient prior to the start of therapy and declares the type of operation required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/20\">",
"     20",
"    </a>",
"    ]. In the population under study, this rate is then compared to the actual operation that was carried out.",
"   </p>",
"   <p>",
"    Unfortunately, few reported series provide results in patients who underwent such prospective assessment by their surgeon and were declared to need an APR before the start of preoperative therapy. The incidence of sphincter preservation in such reports ranges from 39 to 94 percent, averaging 67 percent (",
"    <a class=\"graphic graphic_table graphicRef63971 \" href=\"mobipreview.htm?3/27/3518\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/21-29\">",
"     21-29",
"    </a>",
"    ]. Analyses of local control, survival, and bowel function are encouraging.",
"   </p>",
"   <p>",
"    However, high-quality definitive evidence is lacking that preoperative chemoradiotherapy can consistently convert patients who need an APR to where an LAR is feasible. The German trial of preoperative versus postoperative chemoradiotherapy demonstrated that patients undergoing preoperative chemoradiotherapy were twice as likely to undergo a sphincter-sparing operation (39 versus 19 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the absolute rates of APR in the two cohorts were not significantly different. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'German Rectal Cancer Study'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Mesorectal fascia involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant chemoradiotherapy may also be considered if the preoperative staging evaluation suggests that the tumor invades or &ldquo;threatens&rdquo; (ie, is within 2 mm of) the mesorectal fascia, which is the circumferential resection margin (CRM) when TME is performed. Data from several trials indicate that this finding is highly predictive of residual tumor at the CRM, which places the patient at a high risk of local recurrence and inferior survival. For anterior tumors, the status of the CRM can be predicted by either transrectal ultrasound (TRUS) or MRI, while for posterior or posterolateral tumors, MRI is the preferred strategy. (See",
"    <a class=\"local\" href=\"#H6013599\">",
"     'Locoregional staging: TRUS versus MRI'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=see_link\">",
"     \"Pretreatment local staging evaluation for rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there are fewer data to validate this approach, these patients are appropriate candidates for preoperative chemoradiotherapy in an attempt to downstage the tumor. One of the main benefits for preoperative as compared to postoperative chemoradiotherapy in the German Rectal Cancer Study discussed below (which did not focus on patients with evidence of mesorectal fascia involvement) was a reduction in the rate of local recurrence. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Versus adjuvant chemoradiotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PRETREATMENT STAGING EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is vitally important that patients with newly diagnosed rectal cancer be accurately staged prior to treatment. Staging of distant disease extent as well as locoregional staging modalities are discussed in detail elsewhere; the most important issues are summarized below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=see_link&amp;anchor=H2#H2\">",
"     \"Pretreatment local staging evaluation for rectal cancer\", section on 'History, physical examination and endoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28967?source=see_link\">",
"     \"Endoscopic ultrasound in rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CT scan to evaluate the liver, retroperitoneal nodes, and chest is indicated in all patients. Serum levels of the tumor marker carcinoembryonic antigen (CEA) should be assayed prior to treatment. Elevated pretreatment CEA levels that do not normalize posttreatment imply the presence of persistence disease and the need for further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\", section on 'CT scan'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6013599\">",
"    <span class=\"h2\">",
"     Locoregional staging: TRUS versus MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of appropriate patients for initial radiotherapy or chemoradiotherapy rather than surgery is heavily dependent on accurate preoperative locoregional staging, which is mainly accomplished through physical examination, endoscopy, and imaging evaluation with magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=see_link&amp;anchor=H2#H2\">",
"     \"Pretreatment local staging evaluation for rectal cancer\", section on 'History, physical examination and endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Either TRUS or high-resolution MRI is an acceptable radiographic method to determine preoperative local tumor stage. Both are more accurate than axial CT scans for assessing the depth of tumor invasion, nodal involvement, and the status of the circumferential resection margin (CRM). The choice of either modality may depend on local expertise. However, if available, optimal, thin section (high-resolution) MRI using a surface pelvic phased-array coil MRI is generally preferred when patients are being evaluated for neoadjuvant therapy approaches because of its greater utility in assessing the CRM. TRUS is only able to assess the status of the CRM for anteriorly located tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28967?source=see_link&amp;anchor=H1067157171#H1067157171\">",
"     \"Endoscopic ultrasound in rectal cancer\", section on 'Circumferential resection margin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In practice, the information obtained with TRUS and MRI is often complementary, and at some institutions, both procedures are done preoperatively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=see_link&amp;anchor=H5#H5\">",
"     \"Pretreatment local staging evaluation for rectal cancer\", section on 'Imaging evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NEOADJUVANT CHEMORADIOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of neoadjuvant chemoradiotherapy have focused on two main questions: the comparative benefit of preoperative versus postoperative adjuvant chemoradiotherapy, and the optimal chemotherapy component.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Versus adjuvant chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant chemoradiotherapy had been the standard of care for resectable rectal cancer until a seminal trial from Germany firmly established the role of neoadjuvant chemoradiotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     German Rectal Cancer Study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The seminal German Rectal Cancer Trial randomly assigned 823 patients with clinically staged",
"    <span class=\"nowrap\">",
"     T3/4",
"    </span>",
"    or node-positive rectal cancer to the same chemoradiotherapy regimen administered either preoperatively or postoperatively: 50.4 Gy in 28 daily fractions to the tumor and pelvic lymph nodes concurrent with infusional 5-FU (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for five days during the first and fifth weeks of RT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/30\">",
"     30",
"    </a>",
"    ]. All patients underwent TME and four additional cycles of adjuvant single agent 5-FU (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    bolus daily for five days, every four weeks). Of note, only 5 percent of the patients in either group had",
"    <span class=\"nowrap\">",
"     T1/2,",
"    </span>",
"    node-positive tumors.",
"   </p>",
"   <p>",
"    At 46 month median follow-up, preoperative chemoradiotherapy was associated with a significantly lower pelvic relapse rate (6 versus 13 percent with postoperative therapy); the difference persisted with longer followup, although it was of a lower magnitude at ten years (7 versus 10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/31\">",
"     31",
"    </a>",
"    ]. The five-year disease-free (DFS 68 versus 65 percent) and overall survival rates (76 versus 74 percent) were similar for preoperative and postoperative therapy, respectively; ten year rates were also comparable (DFS, approximately 68 percent in both groups, overall survival approximately 60 percent in both groups) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/31\">",
"     31",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Stage distribution at surgery was suggestive of significant downstaging effects. The",
"    <span class=\"nowrap\">",
"     AJCC/UICC",
"    </span>",
"    stage distribution (I to IV) was 25, 29, 25, and 6 percent for the preoperative group, compared to 18, 29, 40, and 7 percent in the postoperative group. Among 194 patients with low-lying tumors who were thought preoperatively to require APR, those undergoing preoperative chemoradiotherapy were twice as likely to undergo a sphincter-sparing operation (39 versus 19 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3154313\">",
"    <span class=\"h4\">",
"     Prognosis and the extent of tumor regression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A later report of the German Rectal cancer Study focused on prognostic stratification in patients undergoing neoadjuvant chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/32\">",
"     32",
"    </a>",
"    ]. Prognosis was related to the extent of posttreatment tumor regression (",
"    <a class=\"graphic graphic_table graphicRef50210 \" href=\"mobipreview.htm?7/60/8139\">",
"     table 3",
"    </a>",
"    ) and the final tumor stage in the surgical specimen (five-year DFS 86, 95, 81, 65, and 42 percent for ypT0, T1, T2, T3, and T4 tumors, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/33\">",
"     33",
"    </a>",
"    ]), as well as the presence of involved lymph nodes in the surgical specimen (five-year DFS 85, 65, and 18 percent for those with ypN0, N1, and N2 disease, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/32\">",
"     32",
"    </a>",
"    ]. The \"y\" prefix added to the pathologic (p) stage designates a TNM stage (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) that is assigned after multimodality therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41514?source=see_link&amp;anchor=H23#H23\">",
"     \"Pathology and prognostic determinants of colorectal cancer\", section on 'Tumor regression after neoadjuvant therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The poor outcomes seen in patients with ypN+ disease in this and other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/34-37\">",
"     34-37",
"    </a>",
"    ] suggest that these patients are good candidates for novel treatment approaches, such as expanded postoperative chemotherapy.",
"   </p>",
"   <p>",
"    The degree of fibrosis in the pathology specimen can also be used to derive a tumor regression grade, which predicts survival and disease-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Given the characteristic MRI low signal intensity appearance of fibrosis, it has been possible to develop a preoperative MRI-based tumor regression grade stratification system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/40\">",
"     40",
"    </a>",
"    ]. However, whether and how such information should be used to modify the preoperative or postoperative treatment strategy is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     NSABP trial R-03",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative chemoradiotherapy was directly compared to postoperative chemoradiotherapy in NSABP protocol R-03, which randomly assigned patients with rectal cancer to one of two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative therapy, consisting of one cycle of bolus weekly 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      for six weeks, two courses of 5-FU and leucovorin (daily for five days during the first and fifth course of RT) concomitant with pelvic irradiation (50.4 Gy), surgery, then four cycles of postoperative bolus weekly 5-FU and leucovorin.",
"     </li>",
"     <li>",
"      Postoperative therapy, which consisted of surgery, one cycle of weekly bolus 5-FU plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      , two cycles of 5-FU and leucovorin concomitant with pelvic RT as described above, then four cycles of weekly bolus 5-FU and leucovorin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accrual did not reach planned levels, and the protocol was closed early. In the final analysis of 267 enrolled patients, the clinical pathologic complete response rate after preoperative therapy was 15 percent. While preoperative therapy was associated with a significantly higher rate of five-year disease-free survival (DFS, 65 versus 53 percent), there was only a trend toward better overall survival (75 versus 66 percent, p = 0.065), and no difference in locoregional control (five-year cumulative incidence of locoregional recurrence 11 percent in both arms).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19459747\">",
"    <span class=\"h3\">",
"     Korean trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A specific benefit for preoperative chemoradiotherapy could not be shown in a Korean trial that compared preoperative versus postoperative chemoradiotherapy using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    alone (1650",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily during RT) in 240 patients with clinical T3 or N+ rectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/42\">",
"     42",
"    </a>",
"    ]. All patients received four cycles of postoperative capecitabine (2500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily). The complete pathologic response rate was 17 percent after preoperative chemoradiotherapy. At a median follow-up of 52 months, three- and five-year DFS rates were similar in both groups, as was the cumulative rate of local recurrence (3 versus 2 percent). The sphincter sparing rate was similar in the two groups, although among patients with low-lying tumors, the preoperative chemoradiotherapy arm had a higher rate of sphincter-sparing surgery (68 versus 42 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Preoperative chemoradiotherapy versus RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized trials and a meta-analysis have directly addressed the question of whether the concurrent administration of chemotherapy with conventional fractionation RT is critical to the success of this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest trial, EORTC 22921, examined both the benefit of concurrent chemoradiotherapy (using a five-day bolus 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      regimen during weeks 1 and 5 of RT) versus preoperative RT alone (45 Gy over five weeks) and the contribution of postoperative (adjuvant) chemotherapy (four cycles of bolus 5-FU and leucovorin), using a 2 x 2 factorial design [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/44,47\">",
"       44,47",
"      </a>",
"      ]. Compared to RT alone, patients undergoing preoperative chemoradiotherapy had a significantly higher rate of pathologic complete response (pCR, 14 versus 5 percent), significantly less advanced pT and pN stage, and fewer cases with venous, perineural, or lymphatic invasion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/44\">",
"       44",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Pertinent results for all four arms in regards to sphincter preservation and locoregional control are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef50875 \" href=\"mobipreview.htm?25/17/25883\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/47\">",
"       47",
"      </a>",
"      ]. Local failure rates were significantly lower in all three groups receiving chemotherapy, regardless of whether it was given prior to or following surgery. With a median follow-up of 5.4 years, overall survival was comparable in all four groups. Five year progression-free survival was similar in patients receiving preoperative chemoradiotherapy versus RT alone (56 versus 54 percent) and it was not statistically better for those receiving adjuvant chemotherapy versus no adjuvant chemotherapy (58 versus 52 percent, p = 0.13). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Benefit of postoperative chemotherapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In a subsequent meta-analysis of this trial and five others (two of which compared short-course RT versus long-course chemoradiotherapy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/43,45,48-50\">",
"       43,45,48-50",
"      </a>",
"      ], the addition of concomitant chemotherapy to neoadjuvant radiotherapy improved local control (odds ratio for local recurrence 0.56, 95% CI 0.42-0.75) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/51\">",
"       51",
"      </a>",
"      ]. However, there was also a higher rate of acute grade 3 or 4 treatment related toxicity with chemoradiotherapy (OR 3.96, 95% CI 3.03-5.17), and no significant impact on rates of sphincter preservation or overall survival. Comparative pCR rates were not reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the relationship between pathologic stage after neoadjuvant chemoradiotherapy and overall survival that has been shown in many trials and a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/52-54\">",
"     52-54",
"    </a>",
"    ], the reason why higher rates of pCR have not translated into better survival outcomes is not clear. Nevertheless, the addition of chemotherapy to conventional fractionation RT has become a standard approach to neoadjuvant combined modality therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative chemoradiotherapy does not appear to increase the perioperative complication rate from surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/30,41,55,56\">",
"     30,41,55,56",
"    </a>",
"    ]. In the German study described above, the incidence of grade 3 or 4 gastrointestinal toxicity was similar in the preoperative and postoperative chemoradiotherapy groups (28.8 versus 31.7 percent respectively), and postoperative morbidity rates were not higher with neoadjuvant therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/30\">",
"     30",
"    </a>",
"    ]. Significantly fewer patients undergoing neoadjuvant therapy had chronic anastomotic strictures (2.7 versus 8.5 percent).",
"   </p>",
"   <p>",
"    Sacral insufficiency fractures are a relatively uncommon late complication of pelvic radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report, the incidence of sacral insufficiency fractures at three years after preoperative chemoradiotherapy was 3 percent overall; however, women appeared to be at a higher risk (5.8 versus 1.6 percent in men) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A higher rate of sacral insufficiency fractures (7.1 percent) was reported in a retrospective review of 492 patients treated with chemoradiation for rectal cancer over a nine-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/59\">",
"     59",
"    </a>",
"    ]. Independent risk factors associated with fracture were osteoporosis, female sex, and age greater than 60 years.",
"   </p>",
"   <p>",
"    Patients undergoing treatment for rectal cancer are also at risk for sexual dysfunction. The risk is higher in those undergoing APR compared to LAR, in those undergoing non-TME versus TME surgery, and in patients who undergo combined modality treatment that includes RT. The independent contribution of surgical technique (and of nerve preservation in particular) versus that of RT and whether preoperative as compared to postoperative chemoradiotherapy alters rates of sexual dysfunction after treatment for rectal cancer is unknown. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1946?source=see_link&amp;anchor=H98515620#H98515620\">",
"     \"Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery\", section on 'Sexual dysfunction'",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Largely based on the German Rectal Cancer Study Group trial, neoadjuvant chemoradiotherapy with conventional fractionation RT has become a standard approach to treatment of rectal cancer in the United States. The only definitive indication for neoadjuvant chemoradiotherapy, supported by the results of randomized trials, is the presence of a T3 or T4 rectal cancer. However, relative indications for neoadjuvant chemoradiotherapy include the presence of clinically node-positive disease in a patient with an MRI or TRUS-staged",
"    <span class=\"nowrap\">",
"     T1/2",
"    </span>",
"    rectal cancer, a distal rectal tumor for which an APR is thought to be necessary, and a tumor which appears to invade the mesorectal fascia on preoperative imaging, because of the decreased likelihood of achieving a tumor-free circumferential resection margin with upfront surgery. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications for neoadjuvant treatment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=see_link\">",
"     \"Pretreatment local staging evaluation for rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Choice of chemotherapy regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the techniques and dose of irradiation are similar in published chemoradiotherapy studies, there is marked variability in the administration of chemotherapy. Some studies (eg, the German trial described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/30\">",
"     30",
"    </a>",
"    ]) use bolus 5-FU alone while others use bolus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/43,44\">",
"     43,44",
"    </a>",
"    ] for five consecutive days during the first and last weeks of radiation therapy (RT).",
"   </p>",
"   <p>",
"    Some retrospective data suggest that infusional rather than bolus 5-FU during RT increases the likelihood of a pathologic complete response (pCR) in patients with locally advanced rectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/60\">",
"     60",
"    </a>",
"    ]. However, the current preference for concomitant infusional 5-FU during RT by many institutions, including ours, is based mainly upon an Intergroup study that demonstrated superiority of adjuvant concurrent infusional 5-FU compared to bolus 5-FU during RT in patients with resected rectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link&amp;anchor=H8#H8\">",
"     \"Adjuvant therapy for resected rectal cancer\", section on 'Refinements in chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Oral fluoropyrimidines versus infusional 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;The question of whether orally active fluoropyrimidines can replace infusional 5-FU during RT is an unanswered question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H228790748\">",
"    <span class=\"h4\">",
"     UFT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encouraging early results were seen in a nonrandomized trial in which 94 patients with locally advanced but potentially resectable rectal cancer underwent preoperative RT (45 Gy over five weeks) with UFT (an oral combination of the fluoropyrimidine ftorafur (Tegafur) plus uracil that is approved in Europe but not in the United States) five days per week during RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/61\">",
"     61",
"    </a>",
"    ]. The most common treatment-related toxicity &ge;grade 3 was diarrhea (14 percent). The pCR rate was only 9 percent, but an additional 23 percent had only residual microscopic foci of disease at surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H228790766\">",
"    <span class=\"h4\">",
"     Capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Favorable early results have also been seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , which unlike UFT, is available in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/42,62-67\">",
"     42,62-67",
"    </a>",
"    ]. Preliminary reports are available from two randomized trials that compared capecitabine versus infusional FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase III German trial directly compared chemoradiotherapy (50.4 Gy) with concomitant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (825",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily days 1 to 38) versus infusional 5-FU (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      by continuous infusion days 1 to 5, and 29 to 33) in 401 patients with locally advanced rectal cancer who were treated in the neoadjuvant setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/67\">",
"       67",
"      </a>",
"      ]. Patients receiving capecitabine had significantly more hand foot syndrome, fatigue, and proctitis, but less neutropenia. At a median follow-up of 52 months, the local recurrence rate was similar (6 versus 7 percent with infusional FU), but the distant metastasis rate was lower with capecitabine (19 versus 28 percent). Capecitabine was not inferior to FU for five year overall survival, the primary endpoint (75 versus 67 percent, p = 0.0004).",
"     </li>",
"     <li>",
"      NSABP trial R-04 examined the efficacy of four different chemotherapy regimens concurrent with preoperative radiotherapy (45 Gy in 25 fractions over five weeks followed by a boost) in 1608 patients undergoing preoperative chemoradiotherapy for clinical stage II or III rectal cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/68\">",
"       68",
"      </a>",
"      ]. Concurrent chemotherapy consisted of continuous infusion FU (225",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily, five days per week) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly), or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (825",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily five days per week) with or without oxaliplatin (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly).",
"      <br/>",
"      <br/>",
"      In a preliminary report presented at the 2011 ASCO meeting, compared to infusional FU, patients receiving capecitabine had comparable rates of downstaging surgery and sphincter preservation, and similar pathologic complete response rates (22 versus 19 percent for capecitabine and infusional FU); rates of locoregional control, the primary endpoint, were not reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the long-term therapeutic equivalence of daily oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    compared to concomitant intravenous 5-FU during RT for neoadjuvant therapy, albeit with a different toxicity profile.",
"   </p>",
"   <p>",
"    One concern is that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    metabolism is variable, and systemic exposure to capecitabine correlates poorly with efficacy and toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/69\">",
"     69",
"    </a>",
"    ]. The variable bioavailability of oral fluoropyrimidines in individual patients raises concerns as to adequate dosing of these agents. However, if capecitabine is chosen, it is reasonable to use 825",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily, five days per week during RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     5-FU/capecitabine plus other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of adding agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (LV),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    to 5-FU or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    during concurrent chemoradiotherapy is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192757935\">",
"    <span class=\"h4\">",
"     Leucovorin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of metastatic colorectal cancer,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    enhances the efficacy of 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H4#H4\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on '5-FU-based therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The safety and efficacy of a bolus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    plus FU during the first and fifth weeks of pelvic RT was shown in the NSABP R03 trial described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infusional 5-FU has also been combined with LV in an attempt to take advantage of the greater pharmacokinetic advantage of infusional as compared to bolus 5-FU. In a report of 22 patients with locally advanced disease treated using this approach concurrent with RT, treatment was not associated with severe hematologic or gastrointestinal toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/71\">",
"     71",
"    </a>",
"    ]. The pCR rate was 14 percent, 82 percent of patients had a sphincter-saving operation, and the three year survival rate was 69 percent.",
"   </p>",
"   <p>",
"    It is not clear whether these results are better than could be achieved using infusional FU alone. There are no randomized trials of infusional FU with and without concomitant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    during RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192757942\">",
"    <span class=\"h4\">",
"     Oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    has become an important component of treatment for advanced colorectal cancer; in addition, oxaliplatin plus 5-FU and LV outperforms",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    alone in the adjuvant treatment of stage III colon cancer and has been adopted as a standard regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reports from four randomized trials demonstrate greater toxicity and no benefit from an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Italian STAR-01 trial, 747 patients with locally advanced resectable rectal cancer were randomly assigned to preoperative 5-FU-based chemoradiation (50.4 Gy with continuous infusion 5-FU 225",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly), followed by TME [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/72\">",
"       72",
"      </a>",
"      ]. The addition of weekly oxaliplatin significantly increased toxicity (rates of any grade 3 or 4 toxicity during preoperative treatment 24 versus 8 percent) without improving the pathologic complete response rate (pCR, 16 percent in both arms) or sphincter preservation (APR needed in 19 versus 21 percent with and without oxaliplatin, respectively).",
"     </li>",
"     <li>",
"      The multicenter ACCORD",
"      <span class=\"nowrap\">",
"       12/0405",
"      </span>",
"      PRODIGE 1 trial randomly assigned 598 patients with T3 or resectable",
"      <span class=\"nowrap\">",
"       T4N0/1/2",
"      </span>",
"      rectal cancer to concurrent RT (45 Gy in 25 fractions over five weeks) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (800",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily five of every seven days) or concurrent RT (50 Gy in 25 fractions over five weeks) plus the same dose of capecitabine plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/73\">",
"       73",
"      </a>",
"      ]. The addition of oxaliplatin increased toxicity (any grade 3 to 4 toxicity during preoperative therapy 25 versus 11 percent), and did not significantly improve pCR rates (19 versus 14 percent with capecitabine alone), the likelihood of sphincter-preserving surgery (78 versus 75 percent), local control rates (4.4 versus 6.1 percent), or overall survival (88 percent in both groups) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/73,74\">",
"       73,74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the German",
"      <span class=\"nowrap\">",
"       CAO/ARO/AIO-04",
"      </span>",
"      trial, 637 patients with rectal cancer within 12 cm of the anal verge and clinical evidence of perirectal fat or lymph node involvement were randomly assigned to preoperative chemoradiotherapy (50.4 Gy with concurrent FU 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day on days 1 to 5, and 29 to 33), surgery, and adjuvant chemotherapy with bolus FU (500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days, every 29 days for four courses) or preoperative CRT with infusional FU plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , followed by surgery and four months of treatment with modified FOLFOX6 (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/75\">",
"       75",
"      </a>",
"      ]. The addition of preoperative oxaliplatin modestly increased pCR rates (17 versus 13 percent), but there were no differences in the rate of complete (R0) resection; longer follow-up is needed to assess disease-free survival.",
"     </li>",
"     <li>",
"      The previously described NSABP trial R-04 examined the efficacy of four different chemotherapy regimens concurrent with preoperative in patients undergoing preoperative chemoradiotherapy for clinical stage II or III rectal cancer: continuous infusion FU (225",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily, five days per week) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly), or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (825",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily five days per week) with or without oxaliplatin (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/68\">",
"       68",
"      </a>",
"      ]. In a preliminary report presented at the 2011 ASCO meeting, the addition of oxaliplatin to either capecitabine or infusional FU during preoperative chemoradiotherapy did not improve outcomes (pCR rate, percentage of patients who were able to undergo sphincter-pre",
"      <sup>",
"       s",
"      </sup>",
"      erving surgery) but it was associated with significantly higher rates of grade 3 or 4 diarrhea. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    to fluoropyrimidine-based chemoradiotherapy cannot be considered a standard approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192757949\">",
"    <span class=\"h4\">",
"     Irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonrandomized trials suggested benefit for adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    to the chemoradiotherapy regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. However, benefit could not be shown for the addition of irinotecan to 5-FU in a multi-institutional RTOG trial in which 106 patients with",
"    <span class=\"nowrap\">",
"     T3/4",
"    </span>",
"    distal rectal cancer were randomly assigned to continuous infusional 5-FU (225",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily) concurrent with hyperfractionated RT (55.2 to 60 Gy at 1.2 Gy twice daily) or to infusional 5-FU (225",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily, five days per week) plus irinotecan (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once weekly for four weeks) and concurrent conventional fractionation RT (50.4 to 54 Gy in daily 1.8 Gy fractions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/79\">",
"     79",
"    </a>",
"    ]. For patients who had surgery, the pCR rate was similar in both arms (28 percent), as was acute and late toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192757956\">",
"    <span class=\"h4\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early reports suggest that the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a humanized monoclonal antibody targeting the vascular endothelial growth factor, to conventional 5-FU-based chemoradiotherapy provides encouraging pCR rates and does not increase acute toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. However, the impact of this strategy on long-term outcomes and especially posttreatment complications awaits the development and completion of phase III trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H44#H44\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Agents targeting VEGF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192757963\">",
"    <span class=\"h4\">",
"     Cetuximab and panitumumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early reports are mixed regarding the benefit of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    , two humanized monoclonal antibodies targeting the epidermal growth factor receptor, to conventional 5-FU-based chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/82-86\">",
"     82-86",
"    </a>",
"    ]. The impact of this strategy on long-term outcomes and especially posttreatment complications awaits the completion of phase III studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given its long track record, we continue to recommend infusional 5-FU during neoadjuvant during RT, although daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is an appropriate alternative. Guidelines issued by the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    for patients with T3 or T4 rectal cancer indicate that both approaches are acceptable and preferred over bolus FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    concomitant with RT. The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    to fluoropyrimidine-based chemoradiotherapy should not be considered a standard approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Radiation technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the treatment of abdominopelvic tumors, careful attention must be paid to RT technique. It is generally",
"    <strong>",
"     not",
"    </strong>",
"    appropriate to treat rectal tumors with anteroposterior-posteroanterior (AP-PA) fields alone. With this field arrangement, the anterior structures receive high dose; since these structures are not substantially at risk for local failure, the two field technique results in increased treatment-related toxicity without significant improvement in local control. At our institutions, we generally treat patients with a four-field box technique using three-dimensional conformal radiation therapy (3D-CRT), although a three-field with right and left lateral fields and a posterior field is also reasonable. The use of lateral fields permits sparing of a portion of the bladder and some anteriorly placed small bowel.",
"   </p>",
"   <p>",
"    Patients are treated in the prone position. For those with disease limited to the submucosa and muscularis propria, pelvic irradiation to 45 Gy in 25 fractions by a four-field technique is given followed by the first field reduction with lateral fields to 50.4 Gy and a second field reduction (if appropriate) with lateral fields to 54.0 Gy. Patients are treated at 1.8 Gy per day, five fractions per week. For the initial fields (45 Gy), the superior border should be 1.5 cm above the level of the sacral promontory and the lower border of the field 4 to 5 cm below the defined tumor bed. Laterally, the PA-AP fields extend 1 to 1.5 cm beyond the true bony pelvis. To treat the entire presacral space with adequate margins and full dose, the lateral fields are designed so that the posterior border encompasses the entire sacrum with a 1 cm margin posterior to the sacrum. Anteriorly, the fields are designed to encompass the previous tumor bed, including the posterior wall of the vagina for females and a large portion of the prostate for males.",
"   </p>",
"   <p>",
"    After 45 Gy, lateral fields with an approximately 3 cm margin around the marked tumor bed are typically used for three fractions to bring the dose to 50.4 Gy. This is followed by a further field reduction with a 2 cm margin around the marked tumor bed to 54 Gy. A small bowel series must be performed to ensure that no small bowel is within these lateral boost fields.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     NEOADJUVANT RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of trials have compared different schedules of preoperative RT followed by surgery versus surgery alone in patients with rectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/16-19,87\">",
"     16-19,87",
"    </a>",
"    ]. A summary of the results of these studies according to the dose intensity of preoperative irradiation (low dose, moderate dose, and the \"Swedish style\" of short course, high-dose therapy) is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef74961 \" href=\"mobipreview.htm?26/57/27548\">",
"     table 6",
"    </a>",
"    ). The following illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who receive low dose preoperative RT, there appears to be no improvement in local control or survival compared to patients undergoing surgery alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With moderate dose preoperative RT (34.5 Gy given in 15 daily doses of 2.3 Gy), local failure rates are decreased but survival is no better compared to surgery alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a survival benefit for preoperative short course, high dose rate RT compared to surgery alone has been shown in two randomized trials, one from Sweden, and the other, a combined effort by the British Medical Research Council (MRC) and the National Cancer Institute of Canada (NCIC) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/19,87\">",
"       19,87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Short-course, Swedish style RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Swedish study randomly assigned 1168 patients to receive or not receive 25 Gy delivered in five fractions in one week, followed by surgery versus surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/19,88\">",
"     19,88",
"    </a>",
"    ]. After five years, RT was associated with significant improvements in both local control (89 versus 73 percent) and overall survival (58 versus 48 percent). With long-term follow-up, the number of hospital admissions for gastrointestinal disorders (bowel obstruction, abdominal pain) was two- to fourfold higher in irradiated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benefit for this approach was also reported in a",
"    <span class=\"nowrap\">",
"     MRC/NCIC",
"    </span>",
"    trial in which 1350 patients with operable nonmetastatic stage I to III rectal cancer were randomly assigned to preoperative short-course RT (25 Gy in five fractions over one week) or no preoperative RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/87\">",
"     87",
"    </a>",
"    ]. In the control group, selective postoperative chemoradiotherapy (45 Gy with concomitant infusional 5-FU) was recommended only if the surgical specimen had positive circumferential margins (77 of the 676 patients in this group, of whom 53 received it). Both groups were offered postoperative chemotherapy if they had positive circumferential margins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    positive nodes.",
"   </p>",
"   <p>",
"    At a median follow-up of four years, the local recurrence rate was significantly lower with preoperative RT (4.4 versus 11 percent), and for the 596 patients who underwent optimal surgery (with a mesorectal plane of dissection rather than intramesorectal or within the muscularis propria), it was 1 versus 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/89\">",
"     89",
"    </a>",
"    ]. Three-year disease-free survival was significantly better in the group that received preoperative RT (78 versus 72 percent, respectively), but overall survival was similar (80 versus 79 percent). These differences in favor of preoperative short-course RT were noted in all tumor stages and for all tumor locations. A later analysis of self-reported quality of life noted that men who received preoperative RT had significantly greater sexual dysfunction at six months than did those treated with surgery alone and that the difference persisted for up to two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The trial was criticized for including a large number of patients who are not usually considered candidates for RT (including 315 stage I tumors) and because surgery was achieved in the mesorectal plane in only about one-half of enrolled patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87590296#H87590296\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Total mesorectal excision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential for higher rates of long-term toxicity was shown in a Dutch trial, in which 1861 patients with resectable rectal cancer were randomized to total mesorectal excision (TME) alone or high dose rate RT (5 x 5 Gy) followed by TME [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Preoperative RT was associated with an improvement in five-year local recurrence rate compared to TME alone (5.6 versus 10.9 percent) but a similar five-year survival rate (64 percent in both groups) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/7\">",
"     7",
"    </a>",
"    ]. Despite comparable rates of intraoperative and postoperative complications overall, the irradiated group had significantly more perineal wound problems following APR than in those undergoing surgery alone (29 versus 18 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/91\">",
"     91",
"    </a>",
"    ]. They also had more sexual dysfunction and slower recovery of bowel function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/92\">",
"     92",
"    </a>",
"    ], and with long-term follow-up, more fecal incontinence (62 versus 38 percent), anal blood loss (11 versus 3 percent), and dissatisfaction with bowel function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Versus conventional chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative, Swedish-style short course high-dose RT has been directly compared to concomitant fluoropyrimidine-based chemoradiotherapy using conventional fractionation RT in two trials:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A Polish trial involving 316 patients with",
"      <span class=\"nowrap\">",
"       T3/4",
"      </span>",
"      rectal cancer compared conventional fractionation RT (50.4 Gy) in conjunction with bolus 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      during weeks 1 and 5 versus short-course irradiation (5 x 5 Gy fractions with surgery within seven days of the last RT dose) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/48\">",
"       48",
"      </a>",
"      ]. The pCR rate was significantly higher in the conventional chemoradiotherapy group (16 versus 1 percent), and there were fewer cases of radial margin positivity (4 versus 13 percent), but the rate of sphincter preservation in both groups was comparable (58 and 61 percent, respectively). Early radiation toxicity was higher in the chemoradiotherapy group (18 versus 3 percent), but rates of local recurrence (9 versus 14 percent), disease-free survival (58 versus 56 percent) and severe late toxicity (10 versus 7 percent) were not significantly different.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A second trial, the Trans-Tasman Radiation Oncology Group 01.04 trial, randomly assigned 326 patients to short-course RT (5 x 5 Gy fractions) versus conventional standard fractionation chemoradiotherapy (50.4 Gy with concomitant infusional FU) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/49\">",
"       49",
"      </a>",
"      ]. Patients in the short course arm also received six courses of postsurgical adjuvant chemotherapy while those in the conventional fractionation chemoradiotherapy group received four courses. As with the prior trial, the pCR rate was significantly higher with long-course chemoradiotherapy (15 versus 1 percent), but there were no differences in rates of margin positivity or sphincter preservation. At a median follow-up of nearly six years, patients receiving long-course chemoradiotherapy had a 3 percent lower cumulative local recurrence rate at three years (4.4 versus 7.5 percent) and a 2 percent lower cumulative local recurrence rate at five years (5.7 versus 7.5 percent); neither difference was statistically significant. There were also no significant differences in rates of distant recurrences, relapse-free survival, overall survival, or rates of late grade 3 or 4 toxicity. A subset analysis of the 79 patients with distal tumors revealed a cumulative incidence of local recurrence of 12.5 percent for short-course RT and 0 percent for long-course chemoradiotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase III trials (the Swedish Rectal Cancer Trial, the Dutch Trial, and the MRC trial) have demonstrated improved local control in patients with rectal cancer receiving short course preoperative RT followed by surgery versus surgery alone.&nbsp;Only one (the Swedish Rectal Cancer Trial) has shown a survival advantage with short-course preoperative RT versus surgery alone. Two phase III trials (Polish, Australian) have directly compared short course RT to &ldquo;extended&rdquo; course radiation therapy with concurrent 5-FU, although neither was sufficiently powered to show equivalence of the treatments.&nbsp;The results of these studies have shown no statistical differences in local control, sphincter preservation rates, or short term or long term complication rates by treatment arm, although both of the randomized trials comparing short-course RT to long-course chemoradiotherapy showed a nonsignificant trend towards worse local control with short course treatment.",
"   </p>",
"   <p>",
"    In many countries, short course RT has been adopted as the standard preoperative approach for operable rectal cancer. In the United States, short course RT has had limited enthusiasm&nbsp;particularly due to the concern regarding high rates of long term toxicity which the initial studies suggested, but which have not been seen in randomized trials. Some institutions&nbsp;in the United States are now using short course RT prior to rectal surgery in selected patients, such as in the setting of metastatic disease to minimize delays in initiation of systemic therapy. However, in many institutions, long-course chemoradiotherapy is still the preferred approach for most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     BENEFIT OF POSTOPERATIVE CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is uncertainty as to the benefit of postoperative chemotherapy in patients undergoing preoperative chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/94-97\">",
"     94-97",
"    </a>",
"    ], although at least in the US, most oncologists recommend it, and the majority of patients receive it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence used to support this approach is mainly an extrapolation of the proven benefit of postoperative adjuvant therapy with RT and chemotherapy that was the standard of care in the era before preoperative combined modality therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issue of postoperative chemotherapy following preoperative chemoradiotherapy for rectal cancer has been directly addressed in two randomized trials, one of which has been reported only in abstract form:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the previously described EORTC trial 22921, patients who had received preoperative RT with or without chemotherapy underwent a second randomization to four cycles of postoperative 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      or no further therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/47\">",
"       47",
"      </a>",
"      ]. The addition of chemotherapy either before or after surgery significantly improved local control. There were trends favoring adjuvant chemotherapy in both five-year progression-free survival (58 versus 52 percent) and overall survival (67 versus 63 percent), but they were not statistically significant. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Preoperative chemoradiotherapy versus RT'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A later unplanned subgroup analysis limited to the 785 patients who underwent complete (R0) resection and who had no evidence of metastatic disease at surgery (ie, node-negative) revealed that the addition of postoperative chemotherapy significantly improved overall survival in those whose tumors that were downstaged to ypT0-2 but not stage ypT3-4 disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/99\">",
"       99",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      These data raise the possibility that a response to preoperative chemoradiotherapy might serve as a marker for response to postoperative chemotherapy, a finding also noted in at least one retrospective series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/94\">",
"       94",
"      </a>",
"      ]. However, other studies have failed to show a better outcome from postoperative chemotherapy in patients with greater degrees of downstaging from neoadjuvant chemoradiotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/95\">",
"       95",
"      </a>",
"      ]. It is possible that posttreatment pathologic stage represents a prognostic rather than predictive factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/100\">",
"       100",
"      </a>",
"      ], but there are no prospectively collected data with sufficient statistical power to address this question.",
"     </li>",
"     <li>",
"      A prospective randomized cooperative Italian study reported preliminary results of 635 patients treated postoperatively with six cycles of folinic acid and 5-FU compared to observation alone after preoperative chemoradiotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/101\">",
"       101",
"      </a>",
"      ]. The trial was conducted between 1993 and 2003, and the adjuvant chemotherapy regimen was bolus 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      In the latest preliminary report, presented at the 2010 meeting of the European Society for Therapeutic Radiology and Oncology, there was no advantage for postoperative adjuvant chemotherapy either in terms of recurrence rate or overall survival (at five years, 68 versus 70 percent with and without adjuvant chemotherapy, respectively). Ever when the analysis was restricted to patients whose tumors were downstaged to ypT0-2, overall survival rates were approximately 80 percent in both arms of the trial. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, no trial has demonstrated conclusively that additional postoperative 5-FU-based chemotherapy improves outcomes in patients who had neoadjuvant chemoradiotherapy. However, the available data are insufficient to conclude that there is no benefit for postoperative chemotherapy in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from expert groups are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guidelines from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      recommend that all such patients receive chemotherapy even if they have a pCR to neoadjuvant therapy.",
"     </li>",
"     <li>",
"      European Society of Medical Oncology (ESMO) recommendations state that similar to the situation in colon cancer (stage III and &ldquo;high-risk&rdquo; stage II), adjuvant chemotherapy can be provided, even if the scientific support for sufficient effect is less [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, experts convened by a European Rectal Cancer Conference concluded there is insufficient evidence on the benefit of adjuvant chemotherapy after preoperative chemoradiotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until additional data become available, we agree with this approach recommended by the NCCN. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications for neoadjuvant treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Choice of postoperative regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of regimen is also unsettled. One common approach is four cycles of the eight-week Roswell Park regimen of weekly 5-FU and high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (both 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per week for six of each eight weeks for four cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/105\">",
"     105",
"    </a>",
"    ]). Many oncologists use 5-FU alone, extrapolating from guidelines for patients treated with postoperative chemoradiotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of newer regimens containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    has not yet been defined by randomized trials. However, six months of FOLFOX (oxaliplatin plus short-term infusional FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) is increasingly being used in this setting, largely based on the survival advantage of this regimen over leucovorin-modulated 5-FU in the randomized MOSAIC trial, conducted in patients receiving adjuvant therapy for colon cancer. One version of the FOLFOX regimen is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H15#H15\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'MOSAIC trial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some institutions employ a risk-adapted treatment strategy, using an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    - containing regimen preferentially for those patients with lesser degrees of tumor downstaging after preoperative chemoradiotherapy (ie, ypT3-4 or node-positive disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/106\">",
"     106",
"    </a>",
"    ]. However, there is no evidence that this strategy improves outcomes in this group over the use of a fluoropyrimidine-based regimen alone.",
"   </p>",
"   <p>",
"    Future trials may help to define the optimal regimen. Two trials are exploring",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based postoperative chemotherapy regimens in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A European (GERCOR) study, in which patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy were randomly assigned to postoperative",
"      <span class=\"nowrap\">",
"       5-FU/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"        leucovorin",
"       </a>",
"      </span>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      closed in 2004 after accruing 340 patients; results are not yet available. However randomized trials show no benefit from adjuvant irinotecan following resection of colon cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H19#H19\">",
"       \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Irinotecan'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A phase III randomized study of adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      , and 5-FU (FOLFOX) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in patients who have undergone neoadjuvant chemoradiotherapy (concomitant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      , infusional 5-FU or leucovorin-modulated 5-FU) for stage II or III rectal cancer is ongoing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/107\">",
"       107",
"      </a>",
"      ]. The fact that this study was amended to include FOLFOX in both arms reflects its widespread adoption in this setting despite the lack of a trial directly comparing it to leucovorin-modulated 5-FU.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neutropenia may limit the delivery of chemotherapy after pelvic irradiation. In patients with metastatic colorectal cancer, and with adjuvant therapy of colon cancer, FOLFOX is more likely to cause neutropenia than non-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing infusional 5-FU-based combinations (eg, FOLFIRI) (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 5",
"    </a>",
"    ). However, the available data suggest that FOLFIRI is not an active regimen for the adjuvant treatment of colon cancer, and we do not suggest this approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H19#H19\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Irinotecan'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Consensus-based NCCN guidelines suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    modulated FU (",
"    <a class=\"graphic graphic_table graphicRef65525 \" href=\"mobipreview.htm?36/17/37149\">",
"     table 8",
"    </a>",
"    ), FOLFOX (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 7",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (XELOX, (",
"    <a class=\"graphic graphic_table graphicRef61781 \" href=\"mobipreview.htm?13/60/14286\">",
"     table 9",
"    </a>",
"    )) are all appropriate alternatives. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Induction rather than postoperative chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another option that is being explored is the administration of induction chemotherapy prior to chemoradiotherapy rather than following resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/41,84,108-111\">",
"     41,84,108-111",
"    </a>",
"    ]. Early data suggest a more favorable compliance and toxicity profile, but the optimal regimen and long-term impact on outcomes remain undefined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     ALTERNATIVE STRATEGIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Avoidance of radical surgery for complete responders to preoperative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern conventional fractionation concomitant chemoradiotherapy protocols (ie, not the short duration Swedish-style RT approach) can achieve a pathologic complete response (pCR) (ie, no tumor in the surgical specimen) in 16 to 27 percent of rectal cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/32,112-114\">",
"     32,112-114",
"    </a>",
"    ]. Most series report excellent outcomes in patients who achieve a pCR after preoperative chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. A systematic review of data from 16 different datasets, included 1263 patients with a pCR after chemoradiotherapy and 2100 without a pCR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/115\">",
"     115",
"    </a>",
"    ]. At a median follow-up of 55 months for all patients, the five-year overall and disease-free survival rates for patients with a pCR were 90 and 87 percent, respectively. Compared to patients who did not achieve a pCR, a pCR was associated with fewer local recurrences (odds ratio [OR] 0.25, 95% CI 0.10-0.59), less frequent distant failure (OR 0.23, 95% CI 0.11-0.47), and a greater likelihood of being alive at five years (OR 3.28, 95% CI 1.66-6.51).",
"   </p>",
"   <p>",
"    These favorable results have led some to question whether selected patients with radiologic and clinical evidence of a complete response after neoadjuvant chemoradiotherapy might be able to avoid surgery altogether.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7961376\">",
"    <span class=\"h3\">",
"     Observation alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials are available in which patients with a clinical complete response to neoadjuvant chemoradiotherapy were assigned to surgery or no surgery. However, data on long-term outcomes of non-surgically treated patients are available from following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The possibility of avoiding surgical resection was first raised in a study from Brazil, which detailed outcomes of 71 patients (29 percent of the initial cohort of 265 patients) with a protocol-defined complete clinical response (cCR) at eight weeks after chemoradiotherapy, as defined by CT scan with or without EUS (but not MRI), and who were observed without surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/113\">",
"       113",
"      </a>",
"      ]. Their outcomes were compared to those of patients who had a pCR documented at surgery. At a median follow-up of 57 months, there were no cancer deaths in the observed group, no patient experienced a pelvic recurrence, and the only two of the non-surgically treated patients relapsed locally (7 percent, both successfully salvaged); three developed metastatic disease. Five-year disease-specific survival was 92 percent. Among the patients who underwent radical resection (median follow-up 48 months) the pCR rate was 8 percent, there were no local recurrences, and five-year disease-specific survival was 83 percent. The results have been maintained with longer follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/116\">",
"       116",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Interpretation of this experience is limited by its retrospective nature, the lack of modern imaging techniques (particularly MRI), and the fact that 20 percent of the original 265 patients had T2N0 disease, which might favorably affect outcomes. Issues surrounding tumor response assessment are addressed in more detail below. (See",
"      <a class=\"local\" href=\"#H581108\">",
"       'Tumor response assessment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The safety of a &ldquo;wait and see&rdquo; approach rather than immediate surgery for selected clinical complete responders was addressed in a Dutch report of 21 patients (11 percent of the initial cohort of 192) with localized rectal cancer and a cCR to chemoradiotherapy who declined surgery and were managed prospectively in a consistent and well-defined manner [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/117\">",
"       117",
"      </a>",
"      ]. The criteria to define cCR were more stringent than in the Brazilian study; to be eligible for enrollment in the &ldquo;wait and see&rdquo; cohort patients had to have convincing evidence of a cCR on clinical examination, endoscopy, pelvic MRI (which was done in most patients with the paramagnetic contrast agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/49/29461?source=see_link\">",
"       gadofosveset",
"      </a>",
"      ), and biopsy. All patients with positive nodal status at primary staging (17 of 21) received 18 weeks of adjuvant chemotherapy using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      . The control group consisted of a historical cohort of 20 patients with a pCR at radical resection after undergoing chemoradiotherapy for localized rectal cancer, and who had an MRI as a component of restaging after chemoradiotherapy; all but two patients with positive nodal status at primary staging (14 of the 20) received postoperative adjuvant chemotherapy.",
"      <br/>",
"      <br/>",
"      At a median follow-up of 25 months, one of the patients in the observation group had a local recurrence (surgically salvaged) and the rest were alive without disease. Among the control group with a pCR at surgery, at a median follow-up of 35 months, the two-year probability of disease-free and overall survival was 93 and 91 percent, respectively.",
"     </li>",
"     <li>",
"      Less favorable results were reported in a Memorial Sloan-Kettering series of 32 patients who underwent nonoperative management after achieving a clinical complete response to chemoradiotherapy for rectal cancer; outcomes were compared to those of a cohort of 57 patients treated contemporaneously who were found to have a pathologic complete response after undergoing postchemoradiotherapy rectal resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/118\">",
"       118",
"      </a>",
"      ]. There were six local failures in the nonoperative management group (19 percent), of whom three also had a concomitant distant recurrence; there were no local failures in the rectal surgery group. &nbsp;",
"     </li>",
"     <li>",
"      A systematic review of 30 published articles detailing patients treated with a non-operative approach after chemoradiotherapy for rectal cancer included 18 publications from the Habr-Gama group and 12 others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/119\">",
"       119",
"      </a>",
"      ]. The authors concluded that local recurrence rates in modern studies with systematic followup varied from 3 to 50 percent, that definitions of a clinical CR were inconsistent and only in partial concordance with pCR rates, and that patients who are observed and who fail to sustain a clinical CR may fare worse than those who undergo immediate tumor resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/120\">",
"       120",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data suggest that careful endoscopic, clinical, and radiographic evaluation might be able to identify patients who have a good likelihood of local tumor control and who may not need surgery. However, longer-term follow-up, larger numbers of patients and well-designed prospective trials are needed to validate this approach. Surgical resection remains the standard approach after neoadjuvant chemoradiotherapy, even in patients who appear to have a complete clinical response to induction therapy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7961210\">",
"    <span class=\"h3\">",
"     Local excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local excision is an accepted surgical option for T1 rectal cancers. Select patients with deeper (T2) tumors may be adequately treated with a local excision if used in conjunction with preoperative chemoradiotherapy or postoperative RT or chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/121-123\">",
"     121-123",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38137?source=see_link&amp;anchor=H87594804#H87594804\">",
"     \"Overview of surgical procedures for resectable primary rectal cancer\", section on 'Local excision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increasing number of retrospective series report acceptably low local recurrence rates after local excision alone in patients with more advanced disease who have a complete or near-complete response to neoadjuvant chemoradiotherapy, particularly when assessed by modern MRI techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/124-129\">",
"     124-129",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a compilation of data from seven studies of local excision after chemoradiotherapy for clinical T2-3 rectal cancer, there were no local recurrences among 53 patients with ypT0 disease, and local recurrence rates averaged 2 percent in the 45 patients with ypT1 disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/124\">",
"       124",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective series from MD Anderson compared outcomes among 26 patients who underwent local excision (predominantly because they refused APR) versus those of 473 patients who underwent TME; all received preoperative concurrent fluoropyrimidine-based chemoradiotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/125\">",
"       125",
"      </a>",
"      ]. Significantly more patients undergoing local excision had final pathology demonstrating no tumor (49 versus 23 percent), or microscopic-only residual disease (36 versus 19 percent), and far more patients in the TME group had gross residual disease (58 versus 15 percent). Median follow-up was 63 months for the local excision group and 59 months for the TME group. There was no statistically significant difference in the local recurrence rate with local excision versus TME (10.6 versus 7.6 percent). Importantly, a local recurrence developed in 3 of the 13 patients treated with local excision who were initially node-positive, compared to 2 of 34 patients who were initially node-negative by imaging studies. Two of the five local recurrences after local excision were amenable to later salvage surgery.",
"      <br/>",
"      <br/>",
"      There were no significant differences between the two groups with regard to disease-free survival, disease-specific survival, or overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these results seem promising (for appropriately selected patients), prospective studies are needed to demonstrate that long-term outcomes with local excision are comparable to those attained with conventional surgery in patients who achieve a clinical complete response to preoperative chemoradiotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H581108\">",
"    <span class=\"h3\">",
"     Tumor response assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major obstacle to selecting patients who may avoid radical surgery is that a complete pathologic response can most accurately be determined after full pathologic examination of the resected specimen. There is no single test that is capable of identifying patients with complete tumor regression following neoadjuvant therapy. A combination of clinical and endoscopic findings does not provide sufficient information to allow identification of patients with a high suspicion for a pCR (ie, a clinical complete response). The limitations of this approach can be illustrated by the following series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from Memorial Sloan-Kettering, in which all patients undergoing preoperative chemoradiotherapy were subject to resection, 75 percent of the complete clinical responders had persistent foci of tumor that were not detectable on preoperative DRE or proctoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/130\">",
"       130",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study investigated no immediate surgery in ten patients thought to have a &ldquo;complete clinical response&rdquo; to initial chemoradiotherapy according to proctoscopy and biopsy showed disappointing results, with eight recurrences, only four of which were salvaged with radical surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/131\">",
"       131",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the decision to pursue or not pursue surgery should not be based solely on the absence of clinically palpable or visible tumor after neoadjuvant treatment. A major problem is the risk of lymph node metastases despite complete primary tumor regression. Even in ypT0 rectal cancers treated by TME, the risk of lymph node metastases or mesorectal deposits is as high as 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/132-134\">",
"     132-134",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3154313\">",
"     'Prognosis and the extent of tumor regression'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The role of imaging for restaging for assessment of primary tumor and regional nodes after neoadjuvant chemoradiotherapy has been the subject of several studies and all suggest that neither MRI, CT, transrectal endoscopic ultrasound, nor integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    are sufficiently accurate for identifying the true complete responders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/135-143\">",
"     135-143",
"    </a>",
"    ]. A major problem with MRI is that it is difficult to differentiate small areas of residual tumor from fibrosis, and readers tend to overestimate the presence of tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/144-146\">",
"     144-146",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of diffusion-weighted MRI (a functional MR imaging technique that uses differences in the extracellular movement of water protons to discriminate between tissues of varying cellularity) is unclear, with some studies suggesting benefit (particularly in reducing the number of cases in which the presence of tumor in complete responders is overestimated), and another, no additional benefit over standard MRI alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/147-149\">",
"     147-149",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection remains the standard approach after neoadjuvant chemoradiotherapy, even in patients who appear to have a complete clinical response to induction therapy. While promising, prospective validation is needed before either avoidance of surgery or local excision alone can be adopted for any subset of patients undergoing neoadjuvant chemoradiotherapy. A major unresolved issue is accurate nonoperative identification of patients who are complete or near-complete pathologic responders.",
"   </p>",
"   <p>",
"    A prospective trial of nonoperative therapy in complete responders is ongoing at the Royal Marsden Hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/150\">",
"     150",
"    </a>",
"    ]. If successful, this pilot study will aid in the formulation of larger-scale trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Definitive radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectal adenocarcinoma is a radiosensitive malignancy, and RT as curative-intent monotherapy has been used in highly selected patients. When RT is used alone for treatment of rectal cancer, doses must be escalated to achieve optimal local control. To overcome the problem of toxic effects in healthy tissue, studies of RT alone have used endocavitary irradiation in conjunction with either interstitial brachytherapy or external beam RT or both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/151-154\">",
"     151-154",
"    </a>",
"    ]. In the largest series of 199 patients with T1 to T3,",
"    <span class=\"nowrap\">",
"     N0/1",
"    </span>",
"    tumors who were treated with endocavitary radiation with or without external beam RT, the local control rates with RT either alone or followed by surgical salvage were 71 and 81 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/152\">",
"     152",
"    </a>",
"    ]. Tumor size and mobility were independently correlated with outcome. After surgical salvage, the local control rates for mobile T1, mobile T2, and all other lesions were 100, 85, and 56 percent, respectively, while the corresponding five-year recurrence-free survival rates were 100, 90, and 67 percent.",
"   </p>",
"   <p>",
"    Although results from these limited reports are encouraging, they represent carefully selected patients with early stage disease. At present, local excision with or without adjuvant chemoradiotherapy is the preferred approach for T1-2 distal rectal tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38137?source=see_link&amp;anchor=H87594804#H87594804\">",
"     \"Overview of surgical procedures for resectable primary rectal cancer\", section on 'Local excision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with more advanced tumors who are not candidates for surgery, chemoradiotherapy has been successfully applied; however, the results seem inferior to those obtained with combined modality approaches that include surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6299256\">",
"    <span class=\"h2\">",
"     Elimination of pelvic RT in patients with synchronous liver metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no established guidelines for treatment of the rectal primary in patients with synchronous potentially resectable liver metastases. The timing of resection of the primary and the liver metastases (simultaneous versus staged) is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19930?source=see_link&amp;anchor=H5#H5\">",
"     \"Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer\", section on 'Management of the primary cancer in patients presenting with synchronous metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of pelvic RT in patients with synchronous potentially resectable liver metastases is unclear. Approaches to these patients have included adjuvant or neoadjuvant systemic chemotherapy alone combined with resection, preoperative chemotherapy followed by short-course RT and resection, or perioperative chemoradiotherapy conventional fractionation RT followed by resection of both the primary tumor and the metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/155-158\">",
"     155-158",
"    </a>",
"    ]. Guidelines from",
"    <a class=\"external\" href=\"https://subscriptions.nccn.org/login.aspx\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    suggest that any of the following strategies is acceptable: initial chemotherapy followed by resection (synchronous or staged) and postoperative fluoropyrimidine-based chemoradiotherapy, initial chemotherapy followed by chemoradiotherapy and then resection, or initial surgery followed by chemotherapy alone for pT1-2N0 disease, or chemotherapy plus RT for more advanced T-stage or node-positive disease.",
"   </p>",
"   <p>",
"    Information regarding the natural history and patterns of recurrence in patients who undergo complete resection of synchronous rectal cancer and liver metastases has not been well-documented. The following data are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective evaluation of 89 patients presenting with synchronous liver metastases and rectal cancer, 30 percent of whom received perioperative RT, 25 patients (28 percent) developed a pelvic recurrence; the difference between those who did versus did not receive pelvic RT was potentially clinically meaningful though not statistically significant (15 versus 34 percent, p = 0.066) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/156\">",
"       156",
"      </a>",
"      ]. However, there was little influence of pelvic RT on overall survival. In the subgroup of 56 patients who underwent local treatment for the liver metastases, the two-year overall survival rates were 80 versus 74 percent in patients who did and did not receive pelvic RT (p = 0.616). &nbsp;",
"     </li>",
"     <li>",
"      A second retrospective analysis included 185 patients who underwent complete resection of a rectal primary and synchronous liver metastases at a single institution over an 18-year period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/157\">",
"       157",
"      </a>",
"      ]. Chemotherapy was administered to 180 (97 percent), while pelvic RT was given to 91 patients (49 percent), either before (n = 65) or after (n = 26) rectal resection. At a median followup of 44 months, 130 (70 percent) had a disease recurrence, and these recurrences usually involved distant sites (liver, lung) rather than locoregional recurrences at the primary tumor site, even in patients treated without pelvic RT. Overall, pelvic recurrence was an uncommon event and was observed as an isolated episode in &lt;5 percent of patients. Patients who did or did not receive RT had similar rates of recurrence (63 versus 67 percent), pelvic recurrence (11 versus 16 percent), and isolated pelvic recurrence (9 versus 8 percent). In addition, the use of RT did not improve disease-specific survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the setting of potentially resectable stage IV disease, the influence of chemotherapy and RT on overall survival&nbsp;is likely small relative to the survival benefit of&nbsp;surgically resecting all gross disease.&nbsp;In this setting, neoadjuvant chemotherapy and RT may enhance the possibility of an R0 resection.&nbsp;Even&nbsp;when an R0 resection is clearly possible, the prevention of recurrence by the addition of chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT&nbsp;delivered either preoperatively or postoperatively remains a worthy goal&nbsp;as locoregional recurrence can be&nbsp;extremely morbid.&nbsp;Future studies are needed to sort out the relative benefits of both RT and CT in resectable stage IV disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19310186\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE AND SURVIVOR ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for posttreatment cancer surveillance and issues that arise in long-term survivors of rectal cancer (genitourinary problems, bowel and anorectal dysfunction) are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link\">",
"     \"Surveillance after colorectal cancer resection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28202?source=see_link\">",
"     \"Approach to the long-term survivor of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/22/40293?source=see_link\">",
"       \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant or induction chemoradiotherapy is an increasingly used strategy for patients with rectal cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The only definitive indication for neoadjuvant chemoradiotherapy, supported by data from prospective randomized trials, is locally advanced",
"      <span class=\"nowrap\">",
"       (T3/4)",
"      </span>",
"      rectal cancer (",
"      <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for neoadjuvant treatment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with",
"      <span class=\"nowrap\">",
"       T3/T4",
"      </span>",
"      rectal cancers, as defined by transrectal ultrasound (TRUS) or MRI, we recommend preoperative (neoadjuvant) chemoradiotherapy rather than initial resection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Versus adjuvant chemoradiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High quality evidence to support a clear benefit from neoadjuvant chemoradiotherapy as compared to initial surgery for other subgroups of patients with rectal cancer is lacking. Nevertheless, neoadjuvant chemoradiotherapy is an appropriate option in the following settings:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients who have distal mobile rectal cancers are not amenable to local excision. Preoperative chemoradiotherapy might allow some patients to undergo sphincter-preserving low anterior resection (LAR) rather than an abdominoperineal resection (APR). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Distal tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the preoperative staging evaluation suggests the presence of tumor invading or in close proximity (within 2 mm) of the mesorectum. Although randomized trials of preoperative versus postoperative chemoradiotherapy have not been conducted in this population, this finding is highly predictive of residual tumor at the circumferential margin, which places the patient at a high risk of local recurrence. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mesorectal fascia involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       T1/2",
"      </span>",
"      but clinically node-positive rectal cancer. Because of the difficulty in interpreting the status of the perirectal nodes on noninvasive imaging, we suggest a biopsy to confirm the presence of involved lymph nodes prior to embarking on neoadjuvant therapy in these patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'T1/2 and clinically node-positive'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all of these settings, patients must understand that there is a possibility that postoperative chemoradiotherapy might not be needed based upon the final pathologic stage if surgery is performed initially. However, due to a downstaging effect, pathologic nodal staging is unreliable after chemoradiotherapy. Thus, if this approach is followed, a six-month course of postoperative chemotherapy is recommended. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Benefit of postoperative chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The best regimen for neoadjuvant therapy has not been established. For most patients, we suggest conventional fractionation RT with concurrent fluoropyrimidine chemotherapy (ie, long-course chemoradiotherapy) rather than the short-course Swedish approach to RT alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Outside of the United States, short course RT has been adopted in many institutions as the standard preoperative approach for operable rectal cancer. Some institutions&nbsp;in the United States are now using short course RT in selected patients, such as prior to surgery in the setting of metastatic disease to minimize delays in initiation of systemic therapy. However, at many institutions, long-course chemoradiotherapy is still considered the preferred approach for most patients. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Short-course, Swedish style RT'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients undergoing long-course chemoradiotherapy, the best chemoradiotherapy regimen is unsettled. During the five and one-half to six week course of irradiation, we suggest continuous infusion 5-fluorouracil (225",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /24",
"      </span>",
"      hours) during the entire course of RT, as has been used in the postoperative setting for rectal cancer (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/22/42346/abstract/159\">",
"       159",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link&amp;anchor=H3#H3\">",
"       \"Adjuvant therapy for resected rectal cancer\", section on 'Combined chemotherapy plus RT'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (825",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily, five days per week) appears to be equivalent. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Choice of chemotherapy regimen'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We specifically recommend against use of an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -containing chemoradiotherapy regimen, given the greater toxicity and no evidence of added benefit over fluoropyrimidines alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H192757942\">",
"       'Oxaliplatin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical resection remains the standard approach after neoadjuvant chemoradiotherapy for patients who are medically operable, even if they appear to have a complete clinical response to induction therapy. While promising, prospective validation is needed before either avoidance of radical surgery or local excision alone can be adopted for any subset of patients undergoing neoadjuvant chemoradiotherapy. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Avoidance of radical surgery for complete responders to preoperative treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following resection, we suggest that all patients who undergo neoadjuvant chemoradiotherapy receive approximately six months of a 5-FU-based chemotherapy regimen, regardless of the pathologic findings (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The best regimen in this situation is undefined. Reasonable options include FOLFOX (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 5",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (XELOX (",
"      <a class=\"graphic graphic_table graphicRef61781 \" href=\"mobipreview.htm?13/60/14286\">",
"       table 9",
"      </a>",
"      )) weekly bolus 5-FU plus high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      (each 500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly for six of every eight weeks), capecitabine, and single agent 5-FU (500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days every four weeks). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Benefit of postoperative chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/2\">",
"      Wood WC, Willett CG. Update of the Massachusetts General Hospital experience of combined local excision and radiotherapy for rectal cancer. Surg Oncol Clin N Am 1992; 1:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/3\">",
"      Willett CG. Sphincter preservation in rectal cancer. Local excision followed by postoperative radiation therapy. Semin Radiat Oncol 1998; 8:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/4\">",
"      Masui H, Ike H, Yamaguchi S, et al. Male sexual function after autonomic nerve-preserving operation for rectal cancer. Dis Colon Rectum 1996; 39:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/5\">",
"      Havenga K, Maas CP, DeRuiter MC, et al. Avoiding long-term disturbance to bladder and sexual function in pelvic surgery, particularly with rectal cancer. Semin Surg Oncol 2000; 18:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/6\">",
"      Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/7\">",
"      Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/8\">",
"      Chan E, Wise PE, Chakravarthy AB. Controversies in radiation for upper rectal cancers. J Natl Compr Canc Netw 2012; 10:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/9\">",
"      Nissan A, Stojadinovic A, Shia J, et al. Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. J Clin Oncol 2006; 24:4078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/10\">",
"      Guillem JG, D&iacute;az-Gonz&aacute;lez JA, Minsky BD, et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008; 26:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/11\">",
"      Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986; 2:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/12\">",
"      Merkel S, Mansmann U, Siassi M, et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001; 16:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/13\">",
"      Evans J, Patel U, Brown G. Rectal cancer: primary staging and assessment after chemoradiotherapy. Semin Radiat Oncol 2011; 21:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/14\">",
"      Taylor FG, Quirke P, Heald RJ, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011; 253:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/15\">",
"      Allal AS, Bieri S, Pelloni A, et al. Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: feasibility, oncologic results and quality of life outcomes. Br J Cancer 2000; 82:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/16\">",
"      Rider WD, Palmer JA, Mahoney LJ, Robertson CT. Preoperative irradiation in operable cancer of the rectum: report of the Toronto trial. Can J Surg 1977; 20:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/17\">",
"      The evaluation of low dose pre-operative X-ray therapy in the management of operable rectal cancer; results of a randomly controlled trial. Br J Surg 1984; 71:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/18\">",
"      G&eacute;rard A, Buyse M, Nordlinger B, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988; 208:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/19\">",
"      Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997; 336:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/20\">",
"      Minsky BD. Sphincter preservation for rectal cancer: fact or fiction? J Clin Oncol 2002; 20:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/21\">",
"      Wagman R, Minsky BD, Cohen AM, et al. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 1998; 42:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/22\">",
"      Rouanet P, Saint-Aubert B, Lemanski C, et al. Restorative and nonrestorative surgery for low rectal cancer after high-dose radiation: long-term oncologic and functional results. Dis Colon Rectum 2002; 45:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/23\">",
"      Hyams DM, Mamounas EP, Petrelli N, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum 1997; 40:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/24\">",
"      Kuvshinoff B, Maghfoor I, Miedema B, et al. Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: are &lt; or = 1 cm distal margins sufficient? Ann Surg Oncol 2001; 8:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/25\">",
"      Valentini V, Coco C, Cellini N, et al. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys 1998; 40:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/26\">",
"      Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999; 17:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/27\">",
"      Grann A, Feng C, Wong D, et al. Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2001; 49:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/28\">",
"      Gambacorta MA, Valentini V, Morganti AG, et al. Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II-III resectable rectal cancer: a phase II study. Int J Radiat Oncol Biol Phys 2004; 60:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/29\">",
"      Rengan R, Paty P, Wong WD, et al. Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection? J Clin Oncol 2005; 23:4905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/30\">",
"      Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/31\">",
"      Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/32\">",
"      R&ouml;del C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23:8688.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th edition, Edge, SB, Byrd, DR, Compton, CC, et al (Eds) (Eds), Springer, New York 2010. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/34\">",
"      Chang GJ, Rodriguez-Bigas MA, Eng C, Skibber JM. Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer 2009; 115:5432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/35\">",
"      Yeo SG, Kim DY, Kim TH, et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg 2010; 252:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/36\">",
"      Klos CL, Shellito PC, Rattner DW, et al. The effect of neoadjuvant chemoradiation therapy on the prognostic value of lymph nodes after rectal cancer surgery. Am J Surg 2010; 200:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/37\">",
"      Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 2012; 30:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/38\">",
"      Wheeler JM, Warren BF, Mortensen NJ, et al. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. Dis Colon Rectum 2002; 45:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/39\">",
"      Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005; 62:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/40\">",
"      Patel UB, Taylor F, Blomqvist L, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011; 29:3753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/41\">",
"      Roh MS, Colangelo LH, O'Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27:5124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/42\">",
"      Park JH, Yoon SM, Yu CS, et al. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. Cancer 2011; 117:3703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/43\">",
"      G&eacute;rard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24:4620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/44\">",
"      Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. J Clin Oncol 2005; 23:5620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/45\">",
"      Boulis-Wassif S, Gerard A, Loygue J, et al. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Cancer 1984; 53:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/46\">",
"      Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2009; :CD006041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/47\">",
"      Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/48\">",
"      Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/49\">",
"      Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30:3827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/50\">",
"      Latkauskas T, Pauzas H, Gineikiene I, et al. Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery. Colorectal Dis 2012; 14:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/51\">",
"      McCarthy K, Pearson K, Fulton R, Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev 2012; 12:CD008368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/52\">",
"      Quah HM, Chou JF, Gonen M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008; 113:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/53\">",
"      Ruo L, Tickoo S, Klimstra DS, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002; 236:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/54\">",
"      Zorcolo L, Rosman AS, Restivo A, et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol 2012; 19:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/55\">",
"      Enker WE, Merchant N, Cohen AM, et al. Safety and efficacy of low anterior resection for rectal cancer: 681 consecutive cases from a specialty service. Ann Surg 1999; 230:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/56\">",
"      Ulrich A, Weitz J, Slodczyk M, et al. Neoadjuvant treatment does not influence perioperative outcome in rectal cancer surgery. Int J Radiat Oncol Biol Phys 2009; 75:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/57\">",
"      Herman MP, Kopetz S, Bhosale PR, et al. Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys 2009; 74:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/58\">",
"      Inoue Y, Miki C, Ojima E, et al. Pelvic insufficiency fractures after preoperative radiotherapy for rectal carcinoma. Int J Clin Oncol 2003; 8:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/59\">",
"      Kim HJ, Boland PJ, Meredith DS, et al. Fractures of the sacrum after chemoradiation for rectal carcinoma: incidence, risk factors, and radiographic evaluation. Int J Radiat Oncol Biol Phys 2012; 84:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/60\">",
"      Mohiuddin M, Regine WF, John WJ, et al. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys 2000; 46:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/61\">",
"      Fern&aacute;ndez-Martos C, Aparicio J, Bosch C, et al. Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: a phase II multicenter study with 3 years' follow-Up. J Clin Oncol 2004; 22:3016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/62\">",
"      Craven I, Crellin A, Cooper R, et al. Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. Br J Cancer 2007; 97:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/63\">",
"      Kim JC, Kim TW, Kim JH, et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2005; 63:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/64\">",
"      Das P, Lin EH, Bhatia S, et al. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 2006; 66:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/65\">",
"      Krishnan S, Janjan NA, Skibber JM, et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/66\">",
"      Kim DY, Jung KH, Kim TH, et al. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 67:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/67\">",
"      Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012; 13:579.",
"     </a>",
"    </li>",
"    <li>",
"     Roh MS, Yothers GA, O'Connell MJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04 (abstract 3503). J Clin Oncol 2011; 29:221s. (Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=76910 (Accessed on June 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/69\">",
"      Gieschke R, Burger HU, Reigner B, et al. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol 2003; 55:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/70\">",
"      Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/71\">",
"      Lam CW, Chen WT, Liu MT, et al. Effect of preoperative concurrent chemoradiotherapy in locally advanced low rectal cancer after radical resection surgery. Int Surg 2005; 90:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/72\">",
"      Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29:2773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/73\">",
"      G&eacute;rard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/74\">",
"      G&eacute;rard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012; 30:4558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/75\">",
"      R&ouml;del C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/76\">",
"      Navarro M, Dotor E, Rivera F, et al. A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/77\">",
"      Willeke F, Horisberger K, Kraus-Tiefenbacher U, et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 2007; 96:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/78\">",
"      Gollins S, Sun Myint A, Haylock B, et al. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes. J Clin Oncol 2011; 29:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/79\">",
"      Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006; 24:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/80\">",
"      Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27:3020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/81\">",
"      Crane CH, Eng C, Feig BW, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/82\">",
"      Velenik V, Ocvirk J, Oblak I, Anderluh F. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol 2010; 36:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/83\">",
"      Horisberger K, Treschl A, Mai S, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys 2009; 74:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/84\">",
"      Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012; 30:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/85\">",
"      Kim SY, Shim EK, Yeo HY, et al. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. Int J Radiat Oncol Biol Phys 2013; 85:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/86\">",
"      Helbling D, Bodoky G, Gautschi O, et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol 2013; 24:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/87\">",
"      Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/88\">",
"      Birgisson H, P&aring;hlman L, Gunnarsson U, et al. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005; 23:8697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/89\">",
"      Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009; 373:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/90\">",
"      Stephens RJ, Thompson LC, Quirke P, et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol 2010; 28:4233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/91\">",
"      Marijnen CA, Kapiteijn E, van de Velde CJ, et al. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2002; 20:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/92\">",
"      Marijnen CA, van de Velde CJ, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005; 23:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/93\">",
"      Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. J Clin Oncol 2005; 23:6199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/94\">",
"      Janjan NA, Crane C, Feig BW, et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001; 24:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/95\">",
"      Fietkau R, Barten M, Klautke G, et al. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis Colon Rectum 2006; 49:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/96\">",
"      Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 2010; 21:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/97\">",
"      Kiran RP, Kirat HT, Burgess AN, et al. Is adjuvant chemotherapy really needed after curative surgery for rectal cancer patients who are node-negative after neoadjuvant chemoradiotherapy? Ann Surg Oncol 2012; 19:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/98\">",
"      Khrizman P, Niland JC, ter Veer A, et al. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol 2013; 31:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/99\">",
"      Collette L, Bosset JF, den Dulk M, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25:4379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/100\">",
"      Chan AK, Wong A, Jenken D, et al. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61:665.",
"     </a>",
"    </li>",
"    <li>",
"     L. Cionini, A. Sainato, A. De Paoli, et al. FINAL Resuts of randomized trial on aadjuvant chemotherapy after preoperative  chemoradiation in rectal cancer ",
"(abstract 299). Radiother Oncol 2010; 96 (1 suppl); S113. Data presented at the 29th annual meeting of the European Society for Therapeutic Radiology and Oncology, Barcelona, Spain, September 12-16, 2010. Abstract available online at file://www.estro-events.org/Documents/ESTRO29_abstractbook_WEB.pdf (Accessed on January 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/102\">",
"      Nelson VM, Benson AB 3rd. Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy. Curr Oncol Rep 2013; 15:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/103\">",
"      Glimelius B, Oliveira J, ESMO Guidelines Working Group. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/104\">",
"      Valentini V, Aristei C, Glimelius B, et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 2009; 92:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/105\">",
"      Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23:8671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/106\">",
"      Sastre J, Custodio A, Sanchez JC, et al. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer. Anticancer Drugs 2011; 22:185.",
"     </a>",
"    </li>",
"    <li>",
"     Protocol information available online at www.cancer.gov/clinicaltrials/ECOG-E5204 (Accessed on July 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/108\">",
"      Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010; 11:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/109\">",
"      Fern&aacute;ndez-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010; 28:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/110\">",
"      Schou JV, Larsen FO, Rasch L, et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Ann Oncol 2012; 23:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/111\">",
"      Mar&eacute;chal R, Vos B, Polus M, et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol 2012; 23:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/112\">",
"      Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/113\">",
"      Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/114\">",
"      Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg 2012; 99:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/115\">",
"      Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/116\">",
"      Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006; 10:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/117\">",
"      Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011; 29:4633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/118\">",
"      Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg 2012; 256:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/119\">",
"      Glynne-Jones R, Hughes R. Critical appraisal of the 'wait and see' approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg 2012; 99:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/120\">",
"      Habr-Gama A, Perez RO, Proscurshim I, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys 2008; 71:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/121\">",
"      Garcia-Aguilar J, Shi Q, Thomas CR Jr, et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol 2012; 19:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/122\">",
"      Bleday R, Breen E, Jessup JM, et al. Prospective evaluation of local excision for small rectal cancers. Dis Colon Rectum 1997; 40:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/123\">",
"      Lezoche E, Baldarelli M, Lezoche G, et al. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg 2012; 99:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/124\">",
"      Borschitz T, Wachtlin D, M&ouml;hler M, et al. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann Surg Oncol 2008; 15:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/125\">",
"      Callender GG, Das P, Rodriguez-Bigas MA, et al. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol 2010; 17:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/126\">",
"      Bonnen M, Crane C, Vauthey JN, et al. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys 2004; 60:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/127\">",
"      Kim CJ, Yeatman TJ, Coppola D, et al. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg 2001; 234:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/128\">",
"      Ruo L, Guillem JG, Minsky BD, et al. Preoperative radiation with or without chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers. Int J Colorectal Dis 2002; 17:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/129\">",
"      Schell SR, Zlotecki RA, Mendenhall WM, et al. Transanal excision of locally advanced rectal cancers downstaged using neoadjuvant chemoradiotherapy. J Am Coll Surg 2002; 194:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/130\">",
"      Hiotis SP, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 2002; 194:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/131\">",
"      Nakagawa WT, Rossi BM, de O Ferreira F, et al. Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe? Ann Surg Oncol 2002; 9:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/132\">",
"      Stipa F, Zernecke A, Moore HG, et al. Residual mesorectal lymph node involvement following neoadjuvant combined-modality therapy: rationale for radical resection? Ann Surg Oncol 2004; 11:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/133\">",
"      Zmora O, Dasilva GM, Gurland B, et al. Does rectal wall tumor eradication with preoperative chemoradiation permit a change in the operative strategy? Dis Colon Rectum 2004; 47:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/134\">",
"      Habr-Gama A, Perez RO, Nadalin W, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg 2005; 9:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/135\">",
"      Huh JW, Park YA, Jung EJ, et al. Accuracy of endorectal ultrasonography and computed tomography for restaging rectal cancer after preoperative chemoradiation. J Am Coll Surg 2008; 207:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/136\">",
"      Janssen MH, Ollers MC, Riedl RG, et al. Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat Oncol Biol Phys 2010; 77:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/137\">",
"      Kristiansen C, Loft A, Berthelsen AK, et al. PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum 2008; 51:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/138\">",
"      Suppiah A, Hunter IA, Cowley J, et al. Magnetic resonance imaging accuracy in assessing tumour down-staging following chemoradiation in rectal cancer. Colorectal Dis 2009; 11:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/139\">",
"      Vanagunas A, Lin DE, Stryker SJ. Accuracy of endoscopic ultrasound for restaging rectal cancer following neoadjuvant chemoradiation therapy. Am J Gastroenterol 2004; 99:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/140\">",
"      Pastor C, Subtil JC, Sola J, et al. Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings? Dis Colon Rectum 2011; 54:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/141\">",
"      Gollub MJ, Gultekin DH, Akin O, et al. Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. Eur Radiol 2012; 22:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/142\">",
"      Perez RO, Habr-Gama A, Gama-Rodrigues J, et al. Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: long-term results of a prospective trial (National Clinical Trial 00254683). Cancer 2012; 118:3501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/143\">",
"      Zhang C, Tong J, Sun X, et al. 18F-FDG-PET evaluation of treatment response to neo-adjuvant therapy in patients with locally advanced rectal cancer: a meta-analysis. Int J Cancer 2012; 131:2604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/144\">",
"      Barbaro B, Fiorucci C, Tebala C, et al. Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy. Radiology 2009; 250:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/145\">",
"      Dresen RC, Beets GL, Rutten HJ, et al. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part I. Are we able to predict tumor confined to the rectal wall? Radiology 2009; 252:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/146\">",
"      Jonas J, B&auml;hr R. Neoadjuvant chemoradiation treatment impairs accuracy of MRI staging in rectal carcinoma. Gut 2006; 55:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/147\">",
"      Lambregts DM, Vandecaveye V, Barbaro B, et al. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol 2011; 18:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/148\">",
"      Kim SH, Lee JM, Hong SH, et al. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology 2009; 253:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/149\">",
"      Lambregts DM, Maas M, Riedl RG, et al. Value of ADC measurements for nodal staging after chemoradiation in locally advanced rectal cancer-a per lesion validation study. Eur Radiol 2011; 21:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/150\">",
"      O'Neill BD, Brown G, Heald RJ, et al. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol 2007; 8:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/151\">",
"      Coatmeur O, Truc G, Barillot I, et al. Treatment of T1-T2 rectal tumors by contact therapy and interstitial brachytherapy. Radiother Oncol 2004; 70:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/152\">",
"      Aumock A, Birnbaum EH, Fleshman JW, et al. Treatment of rectal adenocarcinoma with endocavitary and external beam radiotherapy: results for 199 patients with localized tumors. Int J Radiat Oncol Biol Phys 2001; 51:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/153\">",
"      Gerard JP, Chapet O, Ramaioli A, Romestaing P. Long-term control of T2-T3 rectal adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys 2002; 54:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/154\">",
"      Lavertu S, Schild SE, Gunderson LL, et al. Endocavitary radiation therapy for rectal adenocarcinoma: 10-year results. Am J Clin Oncol 2003; 26:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/155\">",
"      Herman J, Messersmith W, Suh WW, et al. ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation. Curr Probl Cancer 2010; 34:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/156\">",
"      Kim JW, Kim YB, Kim NK, et al. The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study. Radiat Oncol 2010; 5:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/157\">",
"      Butte JM, Gonen M, Ding P, et al. Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer 2012; 118:5414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/158\">",
"      Shin SJ, Yoon HI, Kim NK, et al. Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases. Radiat Oncol 2011; 6:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/22/42346/abstract/159\">",
"      O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331:502.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2468 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-77.94.48.4-3E90DA3289-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42346=[""].join("\n");
var outline_f41_22_42346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR NEOADJUVANT TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      T3/4 tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H629501194\">",
"      - cT3N0 tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1109524\">",
"      - Contribution of depth of extramural penetration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Relative indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - T1/2 and clinically node-positive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Distal tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Mesorectal fascia involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PRETREATMENT STAGING EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6013599\">",
"      Locoregional staging: TRUS versus MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NEOADJUVANT CHEMORADIOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Versus adjuvant chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - German Rectal Cancer Study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3154313\">",
"      Prognosis and the extent of tumor regression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - NSABP trial R-03",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19459747\">",
"      - Korean trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Preoperative chemoradiotherapy versus RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Choice of chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Oral fluoropyrimidines versus infusional 5-FU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H228790748\">",
"      UFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H228790766\">",
"      Capecitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - 5-FU/capecitabine plus other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H192757935\">",
"      Leucovorin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H192757942\">",
"      Oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H192757949\">",
"      Irinotecan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H192757956\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H192757963\">",
"      Cetuximab and panitumumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Radiation technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      NEOADJUVANT RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Short-course, Swedish style RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Versus conventional chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      BENEFIT OF POSTOPERATIVE CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Choice of postoperative regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Induction rather than postoperative chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      ALTERNATIVE STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Avoidance of radical surgery for complete responders to preoperative treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7961376\">",
"      - Observation alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7961210\">",
"      - Local excision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H581108\">",
"      - Tumor response assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Definitive radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6299256\">",
"      Elimination of pelvic RT in patients with synchronous liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19310186\">",
"      POSTTREATMENT SURVEILLANCE AND SURVIVOR ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2468\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2468|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/11/36020\" title=\"figure 1\">",
"      Mesorectal excision rect CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/30/14819\" title=\"figure 2\">",
"      Anatomy of the anus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2468|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/26/23982\" title=\"table 1\">",
"      2010 TNM staging colorectal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/27/3518\" title=\"table 2\">",
"      Neoadjuvant therapy rectal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/60/8139\" title=\"table 3\">",
"      CRC tumor regression grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/17/25883\" title=\"table 4\">",
"      EORTC trial 22921 rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/20/5454\" title=\"table 5\">",
"      Chemo regimens met CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/57/27548\" title=\"table 6\">",
"      Preop radiation rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 7\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/17/37149\" title=\"table 8\">",
"      Modified de Gramont schedule for gastrointestinal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/60/14286\" title=\"table 9\">",
"      XELOX regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28202?source=related_link\">",
"      Approach to the long-term survivor of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28967?source=related_link\">",
"      Endoscopic ultrasound in rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19930?source=related_link\">",
"      Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1946?source=related_link\">",
"      Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38137?source=related_link\">",
"      Overview of surgical procedures for resectable primary rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41514?source=related_link\">",
"      Pathology and prognostic determinants of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/22/40293?source=related_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=related_link\">",
"      Pretreatment local staging evaluation for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=related_link\">",
"      Surgical oncologic principles for resection of primary rectal adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/37/11866?source=related_link\">",
"      Treatment of locally advanced unresectable or recurrent rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=related_link\">",
"      Treatment protocols for colorectal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_22_42347="Diagnosis of Scedosporium";
var content_f41_22_42347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic tools for Scedosporium infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnostic tool",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Radiographic appearance",
"       </td>",
"       <td>",
"        Lung: variable; alveolar or reticulonodular infiltrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain: hypodense lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microscopy",
"       </td>",
"       <td>",
"        Potassium hydroxide &plusmn; calcoflour white stains: septate, branching hyphae at 45&deg; angles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"2\">",
"        Macroscopic appearance",
"       </td>",
"       <td class=\"sublist_other\">",
"        S. apiospermum: rapid growing, cottony, white or gray, then gray or brown with age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        S.  prolificans: white, cottony, with a greenish gray to dark green reverse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"2\">",
"        Microscopic appearance",
"       </td>",
"       <td class=\"sublist_other\">",
"        S. apiospermum: cylindrical, single, uninucleate, non-pigmented conidiogenous cells; cleistothecia may be produced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        S. prolificans: flask-shaped, basally swollen or inflated, clustered, non-pigmented conidiogenous cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histopathology",
"       </td>",
"       <td>",
"        Septate hyphae branching at 45&deg; angle in inflammation, including granulomata and necrosis; adventitious sporulation may be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Molecular methods",
"       </td>",
"       <td>",
"        Investigational; PCR and sequencing have been used for laboratory identification and outbreak investigations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serology",
"       </td>",
"       <td>",
"        Antibody detection not reliable; (1 &rarr; 3) &beta;-D glucan antigen testing may be helpful, but needs further validation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42347=[""].join("\n");
var outline_f41_22_42347=null;
var title_f41_22_42348="RDA pregnancy and lactation";
var content_f41_22_42348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended daily dietary allowances for adult pregnant and lactating women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pregnant women*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lactating women*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Fat-soluble vitamins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin A",
"       </td>",
"       <td>",
"        770 &micro;g",
"       </td>",
"       <td>",
"        1300 &micro;g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin D",
"       </td>",
"       <td>",
"        600 IU/day (15 micrograms)",
"       </td>",
"       <td>",
"        600 IU/day (15 micrograms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin E",
"       </td>",
"       <td>",
"        15 mg",
"       </td>",
"       <td>",
"        19 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin K",
"       </td>",
"       <td>",
"        90 &micro;g",
"       </td>",
"       <td>",
"        90 &micro;g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Water-soluble vitamins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin C",
"       </td>",
"       <td>",
"        85 mg",
"       </td>",
"       <td>",
"        120 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thiamin",
"       </td>",
"       <td>",
"        1.4 mg",
"       </td>",
"       <td>",
"        1.4 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Riboflavin",
"       </td>",
"       <td>",
"        1.4 mg",
"       </td>",
"       <td>",
"        1.6 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Niacin",
"       </td>",
"       <td>",
"        18 mg",
"       </td>",
"       <td>",
"        17 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin B",
"        <sub>",
"         6",
"        </sub>",
"       </td>",
"       <td>",
"        1.9 mg",
"       </td>",
"       <td>",
"        2 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Folate",
"       </td>",
"       <td>",
"        600 &micro;g",
"       </td>",
"       <td>",
"        500 &micro;g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin B",
"        <sub>",
"         12",
"        </sub>",
"       </td>",
"       <td>",
"        2.6 &micro;g",
"       </td>",
"       <td>",
"        2.8 &micro;g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Minerals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium",
"       </td>",
"       <td>",
"        1000 mg",
"       </td>",
"       <td>",
"        1000 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phosphorus",
"       </td>",
"       <td>",
"        700 mg",
"       </td>",
"       <td>",
"        700 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iron",
"       </td>",
"       <td>",
"        27 mg",
"       </td>",
"       <td>",
"        9 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zinc",
"       </td>",
"       <td>",
"        11 mg",
"       </td>",
"       <td>",
"        12 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iodine",
"       </td>",
"       <td>",
"        220 &micro;g",
"       </td>",
"       <td>",
"        290 &micro;g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Selenium",
"       </td>",
"       <td>",
"        60 &micro;g",
"       </td>",
"       <td>",
"        70 &micro;g",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Females over 18 years old.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Guidelines for Perinatal Care, sixth edition, 2007 and 2010 Institute of Medicine proposed dietary reference intakes for calcium and vitamin D.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42348=[""].join("\n");
var outline_f41_22_42348=null;
var title_f41_22_42349="ADA classification DM";
var content_f41_22_42349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologic classification of diabetes mellitus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 1 diabetes (beta-cell",
"destruction, usually leading to absolute insulin deficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Immune-mediated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Idiopathic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 2 diabetes (may",
"range from predominantly insulin resistance with relative insulin",
"deficiency to a predominantly secretory defect with insulin resistance)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other specific types",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        A. Genetic defects of beta cell function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Chromosome 12, HNF-1-alpha (MODY3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Chromosome 7, glucokinase",
"(MODY2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Chromosome 20, HNF-4-alpha",
"(MODY1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Chromosome 13, insulin",
"promoter factor-1 (IPF-1; MODY4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Chromosome 17, HNF-1-beta",
"(MODY5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        6. Chromosome 2, NeuroD1 (MODY6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        7. Mitochondrial DNA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        8. Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        B. Genetic defects in insulin action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Type A insulin resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Leprechaunism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Rabson-Mendenhall syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Lipoatrophic diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        C. Diseases of the exocrine pancreas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Trauma/pancreatectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Neoplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Hemochromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        6. Fibrocalculous pancreatopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        7. Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        D. Endocrinopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Acromegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Cushing's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Glucagonoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Pheochromocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        6. Somatostatinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        7. Aldosteronoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        8. Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        E. Drug- or chemical-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Vacor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Pentamidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Nicotinic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Thyroid",
"	hormone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        6. Diazoxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        7. Beta-adrenergic agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        8. Thiazides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        9. Dilantin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        10. Alpha-Interferon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        11. Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        F. Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Congenital rubella",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        G. Uncommon forms of immune-mediated diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. \"Stiff man\" syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Anti-insulin receptor",
"	antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        H. Other genetic syndromes sometimes associated with",
"	diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Down's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Klinefelter's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Turner's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Wolfram's",
"	syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Freiderich's ataxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        6. Huntington's chorea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        7. Laurence-Moon-Biedl",
"	syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        8. Myotonic dystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        9. Porphyria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        10. Prader-Willi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        11. Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gestational diabetes mellitus (GDM)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with any form of diabetes may require insulin treatment at some stage of their disease. Such use of insulin does not, of itself, classify the patient.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy;2007 American Diabetes Association From Diabetes Care Vol 30, Supplement 1, 2007. Reprinted with permission from The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42349=[""].join("\n");
var outline_f41_22_42349=null;
var title_f41_22_42350="TNM stage uveal melanoma";
var content_f41_22_42350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging of uveal melanoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Primary tumor (T)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        All uveal melanomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TX",
"       </td>",
"       <td colspan=\"3\">",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T0",
"       </td>",
"       <td colspan=\"3\">",
"        No evidence of primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Iris",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        T1",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Tumor limited to the iris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T1a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor limited to the iris not more than 3 clock hours in size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T1b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor limited to the iris more than 3 clock hours in size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T1c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor limited to the iris with secondary glaucoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        T2",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Tumor confluent with or extending into the ciliary body, choroid, or both",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T2a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor confluent with or extending into the ciliary body, choroid, or both, with secondary glaucoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        T3",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Tumor confluent with or extending into the ciliary body, choroid, or both, with scleral extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T3a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor confluent with or extending into the ciliary body, choroid, or both, with scleral extension and secondary glaucoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T4",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor with extrascleral extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T4a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor with extrascleral extension less than or equal to 5 mm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T4b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor with extrascleral extension more than 5 mm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Ciliary body and choroid - Primary ciliary body and choroidal melanomas, as defined in Figure 51.1, are classified according to the four tumor size categories below:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        T1",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Tumor size category 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T1a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 1 without ciliary body involvement and extraocular extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T1b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 1 with ciliary body involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T1c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T1d",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        T2",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Tumor size category 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T2a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 2 without ciliary body involvement and extraocular extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T2b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 2 with ciliary body involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T2c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T2d",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T3",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor size category 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T3a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 3 without ciliary body involvement and extraocular extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T3b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 3 with ciliary body involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T3c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T3d",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T4",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor size category 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T4a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 4 without ciliary body involvement and extraocular extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T4b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 4 with ciliary body involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T4c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T4d",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        T4e",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Any tumor size category with extraocular extension more than 5 mm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Regional lymph nodes (N)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NX",
"       </td>",
"       <td colspan=\"3\">",
"        Regional lymph nodes cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N0",
"       </td>",
"       <td colspan=\"3\">",
"        No regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N1",
"       </td>",
"       <td colspan=\"3\">",
"        Regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Distant metastasis (M)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td colspan=\"3\">",
"        No distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        M1",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        M1a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Largest diameter of the largest metastasis 3 cm or less",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        M1b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Largest diameter of the largest metastasis 3.1-8.0 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        M1c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Largest diameter of the largest metastasis 8.1 cm or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Anatomic stage/prognostic groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage I",
"       </td>",
"       <td>",
"        T1a",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Stage IIA",
"       </td>",
"       <td>",
"        T1b-d",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2a",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Stage IIB",
"       </td>",
"       <td>",
"        T2b",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3a",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Stage IIIA",
"       </td>",
"       <td>",
"        T2c-d",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3b-c",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4a",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Stage IIIB",
"       </td>",
"       <td>",
"        T3d",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4b-c",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIIC",
"       </td>",
"       <td>",
"        T4d-e",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Stage IV",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M1a-c",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These definitions apply to both clinical and pathologic staging. In clinical practice, the largest tumor basal diameter may be estimated in optic disc diameters (dd, average: 1 dd = 1.5 mm). Tumor thickness may be estimated in diopters (average: 2.5 diopters = 1 mm). However, techniques such as ultrasonography and fundus photography are used to provide more accurate measurements. Ciliary body involvement can be evaluated by the slit-lamp, ophthalmoscopy, gonioscopy, and transillumination. However, high-frequency ultrasonography (ultrasound biomicroscopy) is used for more accurate assessment. Extension through the sclera is evaluated visually before and during surgery, and with ultrasonograpy, computed tomography, or magnetic resonance imaging. When histopathologic measurements are recorded after fixation, tumor diameter and thickness may be underestimated because of tissue shrinkage.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Iris melanomas originate from, and are predominatly located in, this region of the uvea. If less than half of the tumor volume is located within the iris, the tumor may have originated in the ciliary body and consideration should be given to classifying it accordingly.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with permission from: The American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42350=[""].join("\n");
var outline_f41_22_42350=null;
var title_f41_22_42351="Lateral neck radiograph of a child with pneumomediastinum";
var content_f41_22_42351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral neck radiograph of a child with pneumomediastinum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this lateral neck radiograph of a young child with pneumomediastinum, characteristic findings include retropharyngeal lucency (arrowheads), and subcutaneous emphysema of the anterior and posterior neck and anterior chest wall (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ibrahim Janahi and Ammar Saadoon.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_22_42351=[""].join("\n");
var outline_f41_22_42351=null;
